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ABSTRACT OF THE DISSERTATION
MULTIFUNCTIONAL NANOPARTICLES IN CANCER: IN VITRO
CHARACTERIZATION, IN VIVO DISTRIBUTION, AND CELLULAR RESPONSE
AFTER LASER-NIR DYE-INDUCED HEATING
by
Tingjun Lei
Florida International University, 2013
Miami, Florida
Professor Anthony J. McGoron, Major Professor
A novel biocompatible and biodegradable polymer, termed poly(Glycerol malate cododecanedioate) (PGMD), was prepared by thermal condensation method and used for
fabrication of nanoparticles (NPs). PGMD NPs were prepared using the single oil
emulsion technique and loaded with an imaging/hyperthermia agent (IR820) and a
chemotherapeutic agent (doxorubicin, DOX). The size of the void PGMD NPs, IR820PGMD NPs and DOX-IR820-PGMD NPs were approximately 90 nm, 110 nm, and 125
nm respectively. An acidic environment (pH=5.0) induced higher DOX and IR820
release compared to pH=7.4. DOX release was also enhanced by exposure to laser, which
increased the temperature to 42°C. Cytotoxicity of DOX-IR820-PGMD NPs was
comparable in MES-SA but was higher in Dx5 cells compared to free DOX plus IR820
(p<0.05). The combination of hyperthermia (HT) and chemotherapy improved

vii

cytotoxicity in both cell lines. We also explored the cellular response after rapid, shortterm and low thermal dose (laser/Dye/NP) induced-heating, and compared it to slow,
long-term and high thermal dose cell incubator heating by investigating the reactive
oxygen species (ROS) level, hypoxia-inducible factor-1α (HIF-1α) and vascular
endothelial growth factor (VEGF) expression. The cytotoxicity of IR820-PGMD NPs
after laser/Dye/NP HT resulted in higher cancer cell killing compared to incubator HT.
ROS level, HIF-1α and VEGF expression were elevated under incubator HT, while
maintained at the baseline level under the laser/Dye/NP HT. In vivo mouse studies
showed that NP formulation significantly improved the plasma half-life of IR820 after
tail vein injection. Significant lower IR820 content was observed in kidney in DOXIR820-PGMD NP treatment as compared to free IR820 treatment in our biodistribution
studies (p<0.05). In conclusion, both IR820-PGMD NPs and DOX-IR820-PGMD NPs
were successfully developed and used for both imaging and therapeutic purposes. Rapid
and short-term laser/Dye/NP HT, with a low thermal dose, did not up-regulate HIF-1α
and VEGF expression, whereas slow and long-term incubator HT, with a high thermal
dose, can enhance expression of both HIF-1α and VEGF.
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CHAPTER 1: INTRODUCTION
1.1.The cancer problem and current cancer therapy
Cancer has become a serious problem for human society. Currently, it is the 1st and 2nd
leading cause of death in developed and developing countries, respectively (1). Human
cancer involves different and complicated molecular alterations in cells and its causes are
very hard to define. Current clinical therapy for cancer includes chemotherapy,
radiotherapy, surgery, and less commonly hyperthermia (HT) and gene therapy, among
others. It has been shown that the combination of two or more therapies together, such as
radiotherapy with chemotherapy, radiotherapy with HT, or chemotherapy with HT
(chemo-thermotherapy), etc. can achieve better outcomes than do single therapies alone
(2). Traditional diagnostic and therapy techniques have largely proven insufficient for
successful medical management in cancer patients, since they are limited in specificity to
tumor tissue, and too often possess very high toxicity to normal tissues (3, 4). Some
therapies are referred to as “adjuvants”, which are treatments given in addition to the
main or primary treatment and are intended as an enhancement to the primary therapy.
Although there are many therapy methods available today, new methods using advanced
technologies are still required for accurate and precise diagnosis, especially in tumor
imaging and earlier detection. New strategies to lower or eliminate the side effects of
cancer therapy to normal tissues also need to be developed. Among cancer therapies,
chemotherapy has been widely used in clinical treatment since many of the anticancer
drugs bind to DNA and impair DNA function in fast proliferating cells. However, most,
if not all, of these drugs are limited by the fact that they lack specificity, which may result
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in accumulation in normal tissue and exhibit below-therapeutic concentrations at target
tumor tissues (4).
1.2. Nanotechnology and its application in drug delivery
The development of specific drug delivery approaches was first proposed in 1906, the socalled “magic bullet” (5). The advantages of specific targeted delivery of
chemotherapeutic drugs include reducing toxicity in healthy tissue to minimize side
effects and at the same time to maximize the therapeutic outcome in tumors. Thus, the
developing of optimal drug carriers to achieve targeted delivery has been a primary focus
in drug delivery research over the past few decades. Cancer nanotechnology as an
emerging new field is being considered for drug carrier applications. Nanotechnology
involves multiple disciplines of chemistry, biology, medicine and engineering and is
expected to offer many desired cancer therapeutic outcomes with respects to detection,
analysis, and treatment (6, 7). Some successful examples include the use of natural and
synthetic polymeric, metal, and semiconductor nanoparticles (NPs) (8-10), micelles (11),
and liposomes (12, 13). There are also several studies on medical applications. Hood et
al. used polymeric NPs as gene carriers to target to tumor vasculatures (14) and
Harisinghani et al. (15) used superparamagnetic iron oxide NPs to detect prostate cancer.
Among these delivery systems, natural and synthetic polymeric microparticles/NPs and
liposomal delivery systems are very important strategies for cancer drug delivery.
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1.2.1. Particle delivery system
Particles can be used for targeted delivery since they are able to protect the
drugs/genes/bio-molecules from degradation and increase plasma circulation time (reduce
plasma clearance). They are also capable of controlled release and can be tagged with
ligands on the surface providing for specific targeting to corresponding receptors on the
target cells.
1.2.1.1. Liposomal formulation
Liposomes are colloidal particles which are prepared by phospholipid molecules from
either chemical synthesis or natural sources (16). The idea of using liposomes as drug
carriers originated in the 1960s with the discovery that dry lipid films can form spherical
enclosed vesicles after hydration (17). Thirty years after their discovery, investigation of
the potential applications of liposomes on drug delivery intensified in the U.S. after the
Food and Drug Administration (FDA) approved a series of therapeutics based on
liposomes. The good biodegradability and biocompatibility of liposomes encouraged
scientists to investigate their potential to reduce toxicity and enhance the efficacy of the
drug carried in the liposomes. Currently, there are several liposomes and lipid-based
products approved for clinical use in the U.S. (18). The surface charge of liposomes may
be negative, neutral, or positive depending on the lipid head group composition, which
may influence stability and biodistribution, as well as the uptake by targeted cells. To
obtain desired pharmacokinetics of liposome encapsulated drugs for both in vitro and in
vivo applications, it is necessary to design small liposomes (~100 nm diameter) to obtain
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longer systemic circulation time and minimize reticuloendothelial system (RES)
clearance. Researchers have been working on either passive or active targeting of
liposomes, which includes attaching polyethyleneglycol (PEG), monoclonal antibodies
(mAbs), growth factors, or other molecules on liposome surfaces (19). It is expected that
the systemic resident time of liposomes and specificity to targeted tissues may improve
after these surface decorations.
1.2.1.2. Nanoparticles delivery systems
Depending on their size, particles can be divided into 3 different categories:
macroparticles (50-200 µm); microparticles (1-50 µm); NPs (1-1000 nm). Among these
different sizes of particles, NPs are being studied intensively due to their small size and
capability to escape RES uptake, to enter capillaries, and their ease of uptake by cells
through endocytosis. Researchers have been focused on developing lipid, metallic, and
polymeric NPs over the past decade. A plethora of the methods have been reported in the
literature for the preparation of a large number of polymeric based NPs (20-23). Broadly,
these methods can be divided into two categories. The first one is NPs synthesis from the
polymerisation of monomers, where NPs are prepared by polymerisation of monomers or
a mixture of monomers in an aqueous-organic phase or at the interphase of emulsion or
microemulsion. The second category is synthesis from pre-formed polymers in which
NPs are formed by various methods such as salting-out, double emulsion, emulsificationdiffusion and emulsification-solvent evaporation methods (24-27). There are mainly two
different ways to obtain polymeric NPs: from naturally derived polymers or using
synthetic polymers.
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1.2.1.2.1. Naturally derived polymers include fibrin, collagen, chitosan, gelatin, and
starch or cellulose derivatives, among others (28). The advantages of natural polymers
are that they have very good biocompatibility that may positively support cell adhesion
and function, and most of them are biodegradable and usually show low toxicity.
However, naturally derived polymers also have disadvantages, such as potential
immunogenicity, lesser control over their mechanical properties, inconsistency between
batches, risk of animal virus transmission, and high cost due to limited supply (29).
1.2.1.2.2. Synthetic polymers include polyesters such as poly(lactic acid) (PLA),
poly(glycolic acid) and the copolymer of lactic and glycolic acid, i.e. poly(lactide-coglycolide) (PLGA) have been extensively explored. Other common classes of polymers
used to encapsulate drugs in colloidal systems include poly(amino acids),
poly(orthoester)s, and polyanhydrides etc. (30-33). The advantages of using synthetic
biodegradable polymers are: (a) good biocompatibility

and minimize the risk of

biological pathogens or contaminants. (b) controllable biodegradation and release profiles
since the degradation rate can be tailored to meet the requirements from several weeks to
several years (e.g. by altering LA/GA ratio in PLGA copolymers). (c) can be designed
with chemical functional groups that can induce cell growth. (d) specific synthesis
methods can be chosen to obtain compatibility with the specific drugs to be delivered and
with high drug loading efficiency. (e) inexpensive and reproducible in large scale
production with controlled properties.
Synthetic polymers also have disadvantages:

(a) release byproducts which could

influence cell growth, for instance, acidic degradation products (e.g. lactic acid and
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glycolic acid) can be released in the case of PLGA; (b) have poor ability to undergo
processing and can lose of mechanical properties during degradation; (c) chemical
synthesis may include toxic substances.
Among the various polymers that can be used to formulate NPs, PLGA is one of the most
important. It is a co-polymer of lactic acid and glycolic acid and has been studied
intensively since its approval by the FDA for various medical applications. Currently,
there are many studies incorporating therapeutic agents into PLGA NPs and used for
gene/drug/biomolecules delivery, including our lab (20, 34, 35).
PLGA can encapsulate hydrophilic and/or hydrophobic drugs. Hydrophobic species, such
as paclitaxel, doxorubicin (DOX), or quercetin, can be protected by PLGA from
premature degradation so that they can reach their target sites (36). The degradation of
PLGA is usually through hydrolysis of the ester linkages (37). The byproducts after
degradation include lactic acid and glycolic acid, which can be naturally removed from
the body. Extensive studies of PLGA NPs incorporating anticancer drugs have been
reported, including entrapping DOX, paclitaxel, dexamethasone etc. (38-40). The criteria
for using NPs in drug delivery includes: (a) particles have to be compatible with drugs
and achieve high drug loading efficiency; (b) particles have to be stable and have a
controllable drug release profile; (c) biodegradation products have to be safe; (d)
synthesis process has to be inexpensive and reproducible.
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1.2.2. Targeted delivery of NPs
1.2.2.1. Passive targeting
NPs can efficiently reach tumor sites through the enhanced permeability and retention
(EPR) effect arising from the lack of an effective lymphatic drainage system as well as
the presence of vascular endothelial growth factor (VEGF) promoting angiogenesis
which leads to leaky micro-vessels. The endothelial cells in tumor vasculature have loose
interconnections and focal intercellular openings. These breaks in the endothelial cell
lining range in size between 100 to 780 nm, and NPs carrying the required therapeutic
agent can easily extravasate these openings (41, 42), which results in increased
accumulation of drugs in tumor sites and lower toxicity in other healthy tissues without
these vascular properties. The accumulation of NPs in tumor tissue using leaky
vasculature is called passive targeting. Another advantage for using NPs as drug carriers
is they are able to overcome multidrug resistance (MDR) by bypassing drug exporter
pumps (35). MDR may develop in cancer cells due to the cells overexpressing pglycoprotein (P-gp) which pumps out the drugs and compromises the chemotherapy
effect (43).
1.2.2.2. Active targeting
The EPR effect facilitates drug escape from the plasma into the tumor interstitium. More
specific targeting to tumor cells to obtain even higher treatment efficacy can be achieved
by decorating the surface of NPs with appropriate tagging moieties; for instance, ligands,
antibodies, or biomarkers to selectively interact with receptors on the tumor cell
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membrane (18, 44). The tagging of ligands on NPs aiming at particular receptors on
target tissues is called active targeting. There are many ligands that can be used for this
purpose, such as peptides, carbohydrates, and monoclonal antibodies (mAbs). Extensive
research has been focused on mAbs-based cancer therapies which have shown success
towards targeting cancer (45, 46). Initially, mAbs were conjugated directly to the drugs.
However, this method was not very successful since it often changed the function and
bioactivity of the drug during the conjugation process and affected the pharmacokinetics
of the drugs (47, 48). Our lab has shown that conjugating human epidermal receptor
(HER-2) to DOX-loaded PLGA NPs can increase the cellular uptake and cytotoxicity in
the HER-2 receptor overexpressed human ovarian cancer cell line SKOV-3, but not in
negative HER-2 cancer cell lines such as human uterine cancer lines MES-SA and MESSA/Dx5 (Dx5) (35). Thus, conjugating specific antibodies on NPs to target tumor cells
seems to be a promising approach to specific drug delivery.
1.2.3. The development of multifunctional NPs
NPs can possess various functional groups on their surface which allows conjugation to
multiple agents for improved diagnostics and chemotherapeutics. The idea of the
development of multifunctional NPs as a platform for drug delivery has been emerging in
recent years. One important advantage of using NPs as a platform for drug delivery is that
they can incorporate an imaging agent for imaging tumors simultaneously with delivering
chemotherapeutic drugs. Traditional in vivo imaging probes include positron emission
tomography (PET), single photon emission computed tomography (SPECT), gadolinium
compounds in magnetic resonance imaging (MRI). In comparison, the recent
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development of nano-range molecular imaging probes, such as targeted quantum dots,
near-infrared imaging agent encapsulated NPs and other bioengineering NPs provides
several unique features. Their optical and electronic properties could be modified by
changing the size of the particle, therapeutic agents (e.g. anticancer drugs) can be
incorporated into the nanovehicles, and NPs can preferentially accumulate in tumor sites
via the EPR effect.
Optical imaging has high temporal resolution, and the imaging system is usually smaller
and inexpensive as compared to the more traditional imaging techniques, such as
computed tomography (CT), PET/SPECT, MRI etc. However, its clinical application has
been limited by low depth penetration since visible light is highly absorbed and scattered
by human tissue. In this respect, near-infrared imaging dyes (wavelength 700-900 nm)
are promising agents for in vivo optical imaging because light within those wavelengths
has minimal absorption by DNA and water, which improves tissue penetration (49, 50).
Therefore, among a wide range of optical imaging agents, NIR dyes have been studied
extensively for in vivo applications, but not dyes that absorb in the visible range due to
the reasons mentioned before. Some of the NIR dyes can not only be used as imaging
agents but can also act as heat generators due to their unique photothermal properties.
Compounds such as cyanine dyes, phthalocyanine and rhodamine derivatives possess this
quality (51-53). One of the most important NIR dyes is indocyanine green (ICG), since it
is FDA-approved for some medical applications and has been used extensively clinically
with a very good toxicity profile. In the past few decades, it has also been studied for its
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potential use in photodynamic therapy, photothermal therapy and optical imaging (5456).
Hyperthermia (HT) (also called thermal therapy, thermotherapy) is the application of heat
(usually 41°C~45°C) to cancer cells. In some cases, much higher temperature are used to
induce tumor ablation (60°C~80°C for 2~10 seconds), which result in irreversible
destruction of the tumor cells (57). The mechanism of HT is of artificially elevating the
temperature of the tissue with the aim of achieving therapeutic benefits and cancer cell
killing by damaging proteins and structures inside cancer cells. HT is frequently used
together with chemotherapy or radiotherapy to achieve synergistic effects, which can
often result in higher cancer therapy efficacy than radiotherapy or chemotherapy alone.
There are many successful examples in either phase II or phase III clinical trials for
combining HT with radiotherapy, or HT with chemotherapy (58-62). There are also many
other research efforts on NPs application to cancer therapy, one of which is by Park’s
group (63). In their study, DOX-loaded PLGA-Au H-S NPs were fabricated and they
showed that the simultaneous delivery of heat and drugs to tumor sites resulted in
improved cytotoxicity to cancer cells, inhibiting tumor growth and ultimately destroying
the tumor. Currently, gold NPs are being tested for their potential use in photothermal
therapy in phase I human clinical trials (64). In addition to gold NPs, superparamagnetic
iron oxide NPs are also under clinical investigation for the application of HT (65-67).
One of the disadvantages of using gold NPs is they are not biodegradable. As mentioned
above, ICG has also been studied intensively due to its good biocompatibility,
biodegradability, and the ability to produce NIR range fluorescence light and heat after
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excitation by a laser at the appropriate wavelength. One of the challenges for using ICG
is its poor stability in aqueous solution and short plasma residence time (68). Scientists
have been working on encapsulating ICG into NPs, such as PLGA NPs, to increase its
stability and extend its plasma circulation time in vivo (69, 70).

1.3. Novel polymeric NPs poly(glycerol-dodecanoate) (PGD)
As mentioned before, increasing attention has been paid to synthetic polymers for
applications in medicine and surgery over the last decades. Nevertheless, very few
polymers have successfully entered into clinical trials. The chemistry involved in the
synthesis of functional monomers is most often tedious and complex, whereas the
subsequent polymerization is difficult to control. Out of these polymer-based agents,
polyester based NPs in particular, also have good shelf life, suitable physicochemical
properties, and well-characterized degradation products. However, their applications are
potentially limited due to their inherent toxicity. Therefore, there is still a need to explore
novel biodegradable polyesters in order to overcome these disadvantages and develop
clinically translatable drug delivery vehicles.
Migneco and Huang reported the synthesis of a novel polyester from glycerol and
dodecanedioic (DDA) for biomedical applications, which maintains good mechanical and
biological properties during degradation (71). This novel polyester poly(glyceroldodecanoate) (PGD) was formed mainly through ester bonds and its degradation is
through the hydrolysis mechanism. The biodegradation products glycerol and DDA are
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both biodegradable and biocompatible (72, 73). Synthesis of the PGD polymer was by
mixing of glycerol and DDA in 1:1 molar ratio and heating at 120°C for 4~5 days. Cell
growth studies revealed that PGD-treated plates initially show slower human fibroblast
cell growth compared to controls, but at approximately day 18 cell growth in these plates
had reached the same level as for control cell culture plates (71). It seems that this
polymer is a good candidate for use in drug delivery thanks to its good biodegradability
(mainly through surface erosion), biocompatibility, solubility in polar solvents (e.g.
ethanol, acetonitrile), and ease and low cost of synthesis.
1.4. DOX used as chemotherapeutic agent
Chemotherapy is very often used as a first line therapy for cancer management. DOX and
daunorubicin are anthracycline antibiotics which are both often used in human cancer
chemotherapy. The anthracycline effectively kills cancer cells by intercalating to nuclear
DNA and inhibiting topoisomerase II, leading to cell death (74, 75). However, its use has
been limited by toxicity to normal tissues, and because of its lack of tissue or organ
specificity. The main disadvantage of DOX is that it induces irreversible cardiotoxicity,
presumably by localizing in the mitochondria of cardiomyocytes (76). Additionally,
cancer cells can develop multidrug resistance (MDR) through the overexpression of P-gp.
This results in anthracycline drugs being pumped out of the cells, with the subsequent
reduction in therapeutic effect. Scientists are working on incorporating DOX into NPs to
overcome MDR and achieve specific targeting to tumor cells. Several groups have
incorporated DOX into PLGA NPs (38, 77, 78). In our lab, we have successfully
encapsulated DOX into PLGA NPs that are able to bypass MDR and obtain higher
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cellular uptake and cytotoxicity in P-gp overexpressing MES-SA/Dx5 cells compared to
the free form of DOX (35). We further improved the cytotoxicity and cellular uptake of
DOX to SKOV-3 by tagging HER-2 antibody on DOX-loaded PLGA NPs.

1.5. IR820 used as imaging and photothermal agent
As mentioned above, indocyanine green (ICG) has been studied intensively since it is an
FDA-approved NIR dye. ICG (Ex: 785nm, Em: 830nm) can generate NIR range
fluorescence light after being excited by a laser. Compared to visible light, absorption by
human tissue is markedly reduced for NIR light, thus making it appropriate to be used for
in vivo imaging. In our previous work, we have investigated the commercially available
cyanine dye IR820, which could be considered as the alternative to ICG because of
similar optical and thermal properties (79). A recent study by Massoti et al. conjugated
IR820 to polyethylenimine (PEI) for in vivo imaging and DNA delivery (80).
Our study showed the fluorescence quantum yield of IR820 to be lower than that of ICG.
However, IR820 has a non-concentration dependent and more predictable absorption
peak as compared to ICG (79). Also, IR820 is more stable than ICG in aqueous solution
with degradation half-times about double those of ICG. The ability of IR820 to produce
heat after exposure to laser is somewhat less compared to ICG. Our work showed that 5
µM IR820 in cell culture media is able to elevate the temperature from 37°C to 42°C
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during exposure to 3 min laser with power as 1,440 J/cm2, while 5 µM ICG can cause
temperature change from 37°C to 45°C (79). Although a difference exists, the
temperature increase obtained with the use of IR820 is within the range needed for
selective cancer cell HT, and our study showed that IR820 can be used to significantly
inhibit cancer cell growth upon laser exposure in a manner comparable to ICG. In vivo
studies showed that the fluorescent signal from IR820 can be detected for longer periods
than that of ICG (79). The fluorescence signal of IR820 was observed to be stronger than
ICG in both mice and rats 24h after tail vein injection. Rat and mice organ images and
dye content studies in specific organs, measured by homogenizing and extracting the dye,
also showed that IR820 localized to liver, lungs and kidney, and demonstrated stronger
fluorescent signals than ICG in those organs. In sum, IR820 seems to be a good
alternative to ICG because of the characteristics mentioned above.
1.6. Drug release mechanisms in nanoparticles
Drug release from NPs depends upon many factors, such as polymer composition and
morphology, the size and density of the NPs, as well as the physicochemical properties of
the drugs, etc. Generally, the investigation of drug release rate involves: (a) the solubility
of incorporated drug; (b) desorption of the surface bound/adsorbed drug; (c) drug
diffusion through the polymeric NPs matrix; and (d) polymeric NPs matrix
erosion/degradation. Thus, the drug release process is governed by drug solubility,
diffusion and biodegradation of the NPs matrix. If the drug weakly binds or adsorbs to
the surface of the polymer, it may instantaneously dissolve into the releasing solvent,
resulting in an initial “burst” release (81). Diffusion-governed release means that the drug
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is released from the NPs core across the polymer matrix and involves the following steps:
1. penetration of water to NPs; 2. swelling of NPs and 3. drug release from the swollen
NPs matrix. Moreover, in vitro release of the drug can be affected by the solvent pH,
ambient temperature, and the ionic interaction between drug and polymers (82, 83).
Polymer erosion can largely affect drug release from the polymer membrane. Depending
upon the different polymer materials and size, degradation can take place through bulk
erosion or surface erosion. Either one can result in loss of mass from polymer matrices,
swelling of polymers, and changes in polymer morphology and molecular weight, etc.
(84). There are many factors which could influence degradation rate, including
composition of copolymer (85), autocatalysis with acidic degradation products of the
polymer (86), interactions between the polymer and the encapsulated drug (87), etc.
Burkersroda et al. (88) developed a theoretical model to determine whether polymer
erosion occurs through bulk erosion or surface erosion mechanisms. Their model studied
the relationship between the degradation rate constant of polymer functional groups λ and
water diffusivity D, and investigated a parameter called critical device dimension
“Lcritical”. The increase ratio of λ/D, or an increase of L can lead to changes in erosion
mechanisms. L represents the chemical structure dimension of a polymer matrix and if
the polymer matrix dimension is smaller than Lcritical, it will undergo bulk erosion. On the
other hand, if the polymer matrix is larger than Lcritical, it will undergo surface erosion.
1.7.Introduction of hypoxia-inducible factor-1 (HIF-1)
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Hypoxia is often present in the center of solid tumors due to poorly formed vasculature
resulting in low oxygen supply, which could significantly compromise the effect of
chemotherapy and radiotherapy (89-92). It is reported that hypoxia-inducible factor-1
(HIF-1), which includes α and β subunits, could circumvent the anticancer drug effect by
not only escaping drug-induced apoptosis (93, 94), but also through non-apoptotic
mechanisms, such as reducing drug-induced senescence in cancer cells (95).
Radiotherapy could also be affected since oxygen can bind to unpaired electrons and free
radicals that otherwise would damage DNA (90, 96). Therefore, effective radiotherapy
depends on an adequate availability of oxygen. The inadequate oxygen supply could also
result in cancer cell adaptation and lead to expression of various genes in cancer cells,
including VEGF, and pyruvate dehydrogenase kinase 1 (PDK1), which are
transcriptionally regulated by HIF-1 (94, 97).
Given the importance of HIF-1, studies of the effect of HT on this protein are very
relevant for therapeutic HT applications in cancer. Moon et al. reported that HIF-1 can be
up-regulated by mild HT and lead to the expression of VEGF both in vitro and in vivo,
and the increase of VEGF can lead to the promotion of tumor perfusion and
vascularization (98). The detailed molecular mechanism of HT induced HIF-1 expression
was described in Moon’s paper as follows: HT first activates the ERK pathway and
causes an increase of the mRNA expression of NOX1, which promotes NADPH oxidase
and generate reactive oxygen species (ROS) to up-regulate HIF-1α expression. The study
of Goyal et al. and Chandel et al. also demonstrated that the level of one type of ROS,
hydrogen peroxide (H2O2), was increased in cells after NOX1 transfection (99),
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highlighting the importance of H2O2 in HIF-1 activation in cells (100). A corroborating
report by Katschinski’s group also described that heat can stabilize the unphosphorylated
form of HIF-1α and up-regulate HIF-1α expression (101).
ROS was also reported to play a role in the induction of Heat Shock Factor 1 (HSF1) and
mRNA accumulation for HSP70, which belongs to the heat shock protein family (102).
HSP70 can minimize the effect of heat on cells during heat exposure by up-regulating
thermotolerance. This response would compromise the efficacy of HT (103, 104). It has
also been reported by Madamanchi’s group that H2O2 can up-regulate HSP70 protein
levels through the activation of the HSP70 promoter by binding of signal transducers and
activators of transcription (STATs) to the promoters in vascular smooth muscle cells
(VSMCs) (105). This group exposed VSMCs to H2O2 and found that the cytoplasmic
janus tyrosine kinase 2 (JAK2)/STAT pathway can up-regulate HSP70 and minimize
oxidative stress effects on the cells.
Tang’s study investigated the effect of HT on cancer cells in a thermal dose dependent
manner (106). His study showed that HSP70 was not activated by ICG-induced rapid
heating after exposure to laser, and the thermal protective mechanism to cells was not
initiated. The HSP70 activity after rapid, short-term and low thermal dose laser/ICG
heating was low as compared to the increase expression of HSP70 under slow, long-term
and high thermal dose heat accumulation using a cell culture incubator. ICG has been
known to generate singlet oxygens after photoactivation, and Fickweiler et al. suggested
that the cell killing effect of ICG after laser irradiation was mainly due to photodynamic
effect and not the photothermal effect (51). Others have reported that the phothodynamic
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effect would be dominant at low laser densities and high concentrations of ICG, whereas
the photothermal effect would be dominant at higher laser energies (up to 20 W/cm2) and
lower ICG concentrations (54). This is consistent with the notion that the activation of
HSP70 was minimized in a rapid heating modality as described by Tang et al. (106).
As mentioned before, ROS can activate the expression of HSP70. The low expression of
HSP70 during rapid-rate heating could possibly mean the abolishment of ROS
generation, or abolishment of ROS-induced expression of HSP70. Most of the papers
proposing that HT can up-regulate ROS expression and elevate HIF-1 expression and Pgp expression are based on the usage of slower, long-term HT with high thermal dose. It
would be important to investigate if rapid and short-term laser/Dye/NP-induced HT, with
a lower thermal dose, could result in ROS generation and trigger overexpression of HIF-1
and VEGF.
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CHAPTER 2: STATEMENTS AND SPECIFIC AIMS
2.1.Statement of purpose
Due to the unique and advantageous properties of PGD described above, it may be good
candidates for use as a drug delivery vehicle. However, PGD has a low glass transition
temperature (Tg=~32°C), which creates challenges in achieving controlled release of
encapsulated agents. In addition, PGD is hydrophobic, which is not ideal in nanoparticle
formulations for drug delivery purposes. In order to overcome these issues, we modified
PGD polymers by adding malic acid and adjusting the ratio of malic acid to DDA during
the PGD polymer synthesis process in order to adjust the hydrophilicity/hydrophobicity
and have a controllable Tg. The formulation technique does not involve toxic chlorinated
solvents, unlike the formulation of PLGA NPs, and the characteristics of PGMD NPs can
be modified by modulating polymer composition, which provides versatility similar to
that of PLGA. Specifically, the glass transition temperature (Tg) and hydrophilicity of
PGMD NPs can be adjusted by changing the ratio of malic acid to DDA during the
PGMD polymer synthesis process. These properties of PGMD polymer make it a good
candidate for drug delivery applications. With the controllable Tg, we could easily
manage the release profile, and the PGMD NPs can be used for incorporation of
hydrophobic drugs or protein/DNA by adjusting PGMD polymer hydrophilicity. In
addition, PGMD has natural byproducts, such as glycerol, malic acid and DDA, meaning
that it is biocompatible and biodegradable. Following the synthesis of PGMD polymers,
PGMD NPs were also successfully developed. The synthesis of PGMD NPs is easy and
reproducible, and we can prepare uniform PGMD NPs with particles size between 100 to
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150 nm for efficient drug delivery. Our goal is to use these PGMD NPs to incorporate the
anticancer agent DOX and the imaging and photothermal agent IR820 for delivery to
tumors.
Therefore, the purpose of this study was to explore the efficacy of IR820-PGMD NPs and
DOX-IR820-PGMD NPs for cancer therapy with in vitro and in vivo assessment, and lay
the foundations for future development of targeted delivery approaches. IR820-PGMD
NP and DOX-IR820-PGMD NP cytotoxicity in cancer cells were first studied and
compared to free IR820 or free DOX plus free IR820 in MDR cancer cell lines (Dx5) and
non-MDR cancer cell lines (MES-SA). Our previous studies showed that a higher cancer
cell killing effect can be obtained if HT is applied with chemotherapy than by
chemotherapy alone (55). However, in that study drug-loaded NPs were not used to
deliver the HT. Based on those results, it is expected that both IR820-PGMD NPs and
DOX-IR820-PGMD NPs would cause significant cancer cell killing after exposure to
laser compared to the no-laser treated group due to the application of HT. Moreover, both
NP formulations should be more toxic than free IR820, or free IR820 plus DOX)
treatment in Dx5 cells due to NPs can overcome P-gp effect and result in higher cellular
uptake and cytotoxicity to Dx5 than unencapsulated DOX and IR820. In addition, these
particles also have the potential for targeting.
The expression of ROS, HIF-1 and VEGF after exposure to a faster and shorter-term
heating modality with lower thermal dose (laser/Dye/NP HT) were studied and compared
to a slower and longer-term heating system with higher thermal dose (incubator HT). In
the end, the biodistribution and pharmacokinetics studies were performed using both NP
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formulations and the results were compared to free IR820 and DOX. This basic
understanding can serve as a foundation for the ultimate achievement of targeted
chemotherapy-HT NPs mediated cancer therapy.
Most researchers have used Au or ICG as near-infrared imaging and HT agent for highlylocalized HT. Our group was the first to explore the potential use of IR820 or IR820
conjugates as HT agent (79, 107, 108). Several groups, including ours, also analyzed the
potential use of IR820 for imaging (79, 80, 109). To our knowledge, this is the first study
to combine DOX and IR820 together and analyze their toxicity to cancer cells and the
potential of IR820 as an imaging/HT agent after laser irradiation in newly developed
PGMD NPs.
In this study, we investigated multifunctional NP applications in cancer therapy and
measured the cellular response after laser/Dye/NP-induced HT and incubator-induced
HT. The slow but longer-term heating, as discussed before, would induce production of
ROS and activate expression of HIF-1 and VEGF. Tumor angiogenesis occurs partly
through activation of expression of VEGF, which is partially regulated by HIF-1.
Additionally, HIF-1 is partially responsible for tumor reoxygenation and decreased tumor
oxygen consumption, which would be important for radiotherapy. Thus, I believe the
study of ROS, HIF-1, and VEGF expression after laser-induced HT is very important in
order to explore cancer cell responses in fast-induced HT versus more traditional more
slowly-induced HT. In this respect, this research is novel and important being the first to
test the laser/Dye/NP and DOX-laser/Dye/NP cancer cell killing/growth inhibition effect
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in vitro with and without laser exposure, and then to analyze the laser-induced rapid
heating effect on ROS, HIF-1 and VEGF expression.
For this purpose, in vitro cell culture experiments were conducted on the MDR human
uterine sarcoma cancer cell line Dx5 and its non-MDR parent cell line MES-SA. Since
the purpose is to establish the efficacy of the proposed treatment modality on cancer
cells, normal cell lines are not included.
In the end, we are also interested in performing in vivo pharmacokinetics and
biodistribution studies. The purpose of in vivo studies is to compliment the in vitro
studies, which provide valuable but limited information since the in vitro model cannot
predict and represent the complexity of a living system. Animal models are often used to
study a molecular or agent based on the positive in vitro experimental results. We want to
explore the potential application of IR820-PGMD NPs/DOX-IR820-PGMD NPs for in
vivo optical imaging, and identify the difference between nanoformulations and free
drug/dye to see if the NPs can protect the encapsulated agents and result in different
biodistribution and pharmacokinetics result from free drug/dye. In the present study the
in vivo cancer therapy effects of the NP formulations were not tested however.
Therefore, it is hypothesized that the PGMD NPs will be thermal and pH sensitive, thus a
control release of DOX and IR820 will be achieved. The IR820-PGMD NPs and DOXIR820-PGMD NPs will achieve higher cellular uptake and cytotoxicity in MDR cancer
cell lines as compared to free IR820 plus DOX. Also, chemotherapy and HT, when
applied together in NP formulations with the HT induced by exposure to laser and NIR
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absorbing dye, will induce higher cytotoxicity to cancer cells than chemotherapy alone in
both non-MDR and MDR cell lines. In addition, the study will show that the NP
formulation can protect the incorporated agents (DOX and IR820) and prolong their
plasma half-lives, thus widening the diagnostic and therapeutic window. The slow and
longer-term incubator HT, even at a higher thermal dose, does not result in greater cancer
cell killing compared to laser HT. Moreover, incubator HT activates the ROS production
and results in promotion of HIF-1 and VEGF expression. On the other hand, this study
will demonstrate that the combination of HT and chemotherapy in NP delivery form
induces a highly-localized and rapid heat accumulation after exposure to laser, with a
lower thermal dose, but will not activate ROS production and enhance HIF-1 and VEGF
expression, and will result in higher cancer cell killing than in the incubator HT. We
believe the study of ROS, HIF-1 and VEGF expression in cancer cells after laser
exposure is very important with respect to addressing the effect of different heating rates
and thermal doses to cancer cells. We used incubator–induced HT to mimic whole-body
HT, and the comparison between incubator HT and laser/Dye/NP HT may provide
important information on the effects of different modalities of HT used in cancer therapy.
In the end, I believe this study will provide an extension to the current knowledge of
thermo-chemotherapy delivery in NP form, and will bring significant impact to the
application of nanotechnology on cancer therapy.
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2.2. Specific aims
Aim 1, incorporation of IR820 and DOX into void PGMD NPs and characterization of
IR820-PGMD NPs and DOX-IR820-PGMD NPs, including Fourier Transform InfraRed
(FTIR) spectroscopy, Scanning Electron Microscopy (SEM), Dynamic Light Scattering
(DLS) measurements, drug loading efficiency and release kinetics studies in different pH
buffer and with exposing NPs to laser. Cell culture experiments were conducted for
studying IR820-PGMD NPs and DOX-IR820-PGMD NPs in both MES-SA and Dx5,
including cellular uptake of NPs, NP subcellular localization, NP intracellular fate in the
cytoplasm and their cytotoxicity.
Aim 2, determine the production of ROS after laser/Dye/NP-induced HT and compare
the results to incubator-induced HT. Then, HIF-1 and VEGF expression were
investigated following ROS study. To accomplish this aim, IR820-PGMD NPs were used
in an established laser induced rapid heating system to investigate the heating rate and
thermal dose effect to the expression of ROS, HIF-1 and VEGF within cells. These
results were compared to an incubator HT system, which is used to mimic the traditional
whole body HT. The thermal dose of laser/Dye/NP HT and incubator HT was calculated
by a cumulative equivalent minutes at 43 degree Celsius (CEM43) mathematical model.
Aim 3, pharmacokinetics and biodistribution studies were done in mice. Mouse model
was chosen due to their low cost and ease of handling. In addition, the mouse model had
been well established for preclinical drug testing to determine their pharmacokinetic
behavior and safety before use in humans. Therefore, mice were used to study the
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biodistribution and pharmacokinetics of IR820-PGMD NPs/DOX-IR820-PGMD NPs,
and the results compared to free IR820 and free DOX.
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CHAPTER 3: METHODOLOGY
3.1.The fulfillment of Specific Aim 1
3.1.1. Preparation and characterization of PGMD polymer, void PGMD NPs, IR820PGMD NPs and DOX-IR820- PGMD NPs
Doxorubicin hydrochloride (DOX-HCl; MW 579.95) was purchased from Waterstone
Technology (Waterstone Technology, CA). Malic acid, 1, 12-Dodecanedioic acid (DDA),
dimethylsulfoxide (DMSO>99.9%, reagent grade), pluronic F-127, micro bicinchonic
acid (BCA) protein assay kits, Dulbecco’s phosphate-buffered saline (DPBS), phosphate
buffered saline (PBS), IR820, penicillin–streptomycin solution, tetrahydrofuran (THF)
and trypsin-EDTA were purchased from Sigma-Aldrich (Sigma, Louis). PGMD polymers
were prepared following Mingueo’s paper with the modification of adding malic acid.
Briefly, glycerol (MP Biomedical, LLC, Solon OH) and a combination of DDA and
malic acid in 1:1 molar ratio was mixed and heated up to 120°C for 48 hours. The molar
ratio of DDA to malic acid was 7:3. After that, the mixture was placed under vacuum and
continuous stirring for 24 hours. The synthesis of void PGMD NPs, IR820-PGMD NPs
and DOX-IR820-PGMD NPs were performed using the oil-in-water emulsification
solvent evaporation method. Briefly, approximately 2 mg DOX-HCL and 2 mg IR820
were measured and added to 400 µL methanol, then mixed with 0.8 mL acetonitrile
containing around 12 mg PGMD polymer. The mixed solution was added to 12 mL 0.1%
pluronic while stirring at 930 rpm. The organic phase was removed by evaporation for 24
hours at room temperature. The NPs were then collected and centrifuged at 5000 rpm for
5 minutes to remove large NPs.
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Next, the supernatant was collected and any free DOX or IR820 was filtered out using a
dialysis membrane at MWCO 1,000 Da. The dialysis process was continued for 24 hours.
Finally, the particles were freeze-dried and lyophilized for 48 hours. Void PGMD NPs
were prepared following a similar method except for the addition of DOX and IR820.
IR820-PGMD NPs were also prepared following the same protocol, except that no DOX
was added.
3.1.2. Characterization of PGMD polymer, void PGMD NPs, IR820-PGMD NPs and
DOX-IR820-PGMD NPs
3.1.2.1. Characterization of PGMD polymer
Glass transitional temperature (Tg) of PGMD was measured through differential scanning
calorimetry (DSC) by using a DSC 2910 (TA instrument, New Castle, DE). Fourier
transform infra-red (FTIR) spectra were obtained through a Perkin Elmer Spectrum 1000
spectrometer (Perkin Elmer, Waltham, MA). The molecular weight (MW) of the polymer
was determined by a calibration curve of standard polystyrene (TSKstandard polystyrene,
TOSOH, Japan) measured with a gel permeation chromatography (GPC) column (Jordi
lab, Bellingham, MA) at 0.5 mL/min flow rate in THF.
3.1.2.2. NPs size, size distribution and zeta potential
Void PGMD NPs, IR820-PGMD NPs and DOX-IR820-PGMD NPs size were measured
by dynamic light scattering (DLS) using a Malvern Zetasizer (Malvern Instruments,
Worcestershire, United Kingdom). Size measurements were taken at 25°C using a 1:30
(vol/vol) dilution of the NPs suspension in deionized (DI) water. The polydispersity
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index (PDI) was used as a measure of particle size distribution. Zeta potential (surface
charge) of the NPs dispersed in DI water was measured by the same Zetasizer. The size
of void PGMD NPs was confirmed with SEM (SEM, JEOL-JEM).
3.1.2.3.Drug loading
The NPs were dissolved in DMSO (1 mL), and the absorption spectrum of the samples
was evaluated using a Cary spectrophotometer (Varian, Palo Alto, CA). Serial dilutions
of the sample was done to reach the linear range (1:2, 1:4, 1:8, 1:16, 1:32, 1:64 dilutions).
The maximum peak intensities were corrected with DMSO blank subtraction and were
plotted and fitted to a linear model. Then, the concentration of DOX and IR820 in the
NPs were determined using a standard calibration curve of DOX and IR820 in DMSO
using the same spectrophotometer. IR820 concentration in IR820-PGMD NPs was
measured following the same method using a calibration curve of IR820 in DMSO.
3.1.3. NIR laser-IR820 HT delivery system
3.1.3.1. System set-up
In order to deliver rapid HT to the cells, IR820 has to be first taken up by cells and then
activated by a NIR laser. For this purpose, a laser heating system was designed (55). The
system includes a laser module (RLDH808-1200-5, Roithner Laserthchnik, Austria), a
laser holder, a heated stage insert (WPI Heated Stage Insert, World Precision Instruments
Inc, Sarasota) and a mobile stage with an extension arm. External cover of the system is
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also designed for safety consideration; power supplies for the laser and the heated stage
insert are also placed outside the box for the same reason.
During operation, the whole system is covered within a wooden box to eliminate effects
of air currents and also to prevent the laser light from exiting. The laser module is fixed
to a holder, so that its beam is perpendicular to the 96-well plate which is placed on the
heated stage insert. The heated stage insert is powered by an external source to ensure
that the plate is at 37°C prior to the laser application.
The NIR laser source emits light at 808 nm with an output power of 1.2 Watts. The
calculated power density is 1440 J/cm2. This small spot size guarantees that only one well
is excited at a time. The exact positioning of a well with the laser beam is achieved by
moving the stage with an extension arm. The arm is used to move the wells in the plate,
thereby allowing different wells to be exposed to the laser one at a time without opening
the box.
To verify the positioning of the laser relative to the wells, an infrared beam finder card
(IRC-42R) is used to visualize the NIR laser beam while wearing protective goggles. At
the same time, the specific well under exposure and its relative position outside the box is
indicated by a position indicator on another 96-well plate. After moving through A1 to
H12 of a 96-well plate using the moving stage, the relative position outside the box is
recorded for future use. Necessary safety measures are taken and personal protective
equipment

used

during

experiments,

especially

administrative controls.
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engineering
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3.1.3.2. System calibration
Temperature calibration studies were carried out with the NIR laser system. The purpose
is to find the optimal settings for the heated stage insert controller so that a well filled
with 222 µL of media could be maintained at 37°C. The temperature distribution across
the entire 96-well plate when using the heated stage insert is monitored. During this
calibration process, a 96-well plate filled with 222 µL of media is placed on the heated
stage insert and the settings on the heated stage controller adjusted so that the temperature
in the wells is at 37°C. Twenty minutes time interval is given for steady state heat
transfer. Finally, the temperature of each well is recorded with a thermocouple, which is
inserted into a 96-well plate to measure the medium temperature change to generate a
temperature distribution profile. The temperature distribution of the 96-well plate is
shown in Table 1 (55).
1

2

3

4

5

6

7

8

9

10

11

12

A

29.3

33

35.8

36.1

36.8

35.9

36.9

36.9

36.8

35.7

33.2

29.8

B

30.2

34.4

36.8

36.7

37.1

36.8

36.5

36.9

36.6

36.8

34.8

32.7

C

32.5

35

37.4

37.1

37.2

37.1

37.2

37.3

37.1

37.2

35.7

33.8

D

35.2

35.6

37.5

37.4

37

36.0

36.9

37.4

37.2

37.3

35.7

34.1

E

32.3

35.5

37.6

37.2

37.1

35.1

37.4

37.1

37.3

37.1

35.9

33.9

F

33.4

35.4

37

37.1

37.1

36.9

37.1

37.1

37.5

37.1

35.8

33.7
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G

31.1

34.1

36.5

36.8

36.9

36.7

37.5

37.2

37.4

36.7

35.1

31.3

H

29.1

33.2

35.7

35.9

36.5

36.4

37.1

36.9

36.7

35.8

34.7

29.6

Table 1. A 96-well plate temperature distribution when placed on the heated stage insert.
Since there is a hole in the center of the heated stage, which results in a nonhomogeneous temperature distribution in the 96-well plate, we designed our experiments
accordingly to use the wells which can reach the temperature between 36.5°C – 37.5°C
(bold).
3.1.3.3. Heating capacity of free IR820 and IR820 in IR820-PGMD NPs and DOXIR820-PGMD NPs
We prepared 2.5 μM, 5 μM, and 10 μM solutions of IR820 or NPs which have equivalent
concentration of IR820. Each sample was added to three wells in a 96-well plate sitting
on the heated stage insert, and excited with the laser system described in section. 3.1.3.1.
for 180 seconds. Temperature inside the well was measured with a thermocouple for the
duration of exposure, and the three-well values for a given dye were averaged.
1

2

3

4

5

6

7

8

9

A
B

M

2.5

5

10

M

2.5

5

10

M

2.5

5

10

C
D
E
F

31

10

11

12

Table 2. Schematic of IR820 study design for measuring temperature profile in a 96-well
plate (n=3); M: wells with only media; wells labeled with 2.5, 5, 10, indicates the final
concentration of IR820 in the well.
The goal of this study was to find out an optimal concentration at which IR820 is able to
heat up the cells to approximately 42°C quickly. A volume of 22 µL of free IR820,
IR820-PGMD NPs, or DOX-IR820-PGMD NPs at IR820 concentrations of 25 µM, 50
µM, and 100 µM were added to the wells that were originally loaded with 200 µL media
to achieve final concentrations of 2.5 µM, 5 µM, and 10 µM.
3.1.4. Incubator-induced HT and temperature profile
In order to mimic conventional whole body HT, a Hera incubator was used as the energy
source. The temperature of the incubator was set to 42°C. Ninety-six-well plates, which
were originally incubated in the 37°C incubator, were transferred to the 42°C incubator.
To study the temperature profile of incubator HT, we first placed the thermocouple inside
the incubator and the sensor tip was inserted into a 96-well plate to measure the medium
(222 µL) temperature change.
3.1.5. Thermal dose calculation
The term “thermal isoeffective dose” is used to compare different time-temperature
combinations which produce the same cell killing effect. This method was used since the
cell death rate under HT is exponentially related to both time and temperature. The
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relationship of time and temperature can be expressed mathematically by the following
isoeffect equation:
∗

(Equation 1)

where t1 & t2 are the duration of treatment at temperature T1 & T2, respectively.
Originally, R is a function of temperature, however, an estimation of R as a constant will
give an error of less than 2% in the temperature between 37°C to 46°C described by
Sapareto et al. (110). Hence, R is assumed to be 0.5 above 42°C and 0.25 below 43 °C
(110). Based on Equation (1), different thermal doses can be converted to the cumulative
equivalent minutes at 43°C (CEM43). From Equation (1), we did a slight modification and
set T1 to be 42°C and T2 to vary during heat treatment, so that we obtain Equation (2).
The integral upper limit t is the end time of the experiment (3 minutes or 60 minutes).
(Equation 2)

After obtaining the temperature profile during both incubator and laser/Dye/NP HT, the
CEM42 model was applied to calculate the thermal doses in each treatment.
3.1.6. In vitro studies of void PGMD NPs, IR820-PGMD NPs and DOX-IR820-PGMD
NPs
To fulfill this part of aim 1, human uterine sarcoma MES-SA cells, and their MDR (P-gp
overexpressing derivative MES-SA/Dx5 (Dx5)) cells, human ovarian carcinoma cancer
cells (SKOV-3), McCoy's 5A medium, and fetal bovine serum were purchased from
American Type Culture Collection (Manassas, Virginia). 24-well tissue culture plates, d-
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poly coverslips, and formalin were purchased from Fisher Scientific. All the cells were
cultured in McCoy's 5A medium added with 1% penicillin and 10% fetal bovine serum,
and kept in a 37°C cell incubator with a humidified atmosphere of 5% CO2 and 95% air.
3.1.6.1.IR820 and DOX release kinetics profile from DOX-IR820-PGMD NPs
Briefly, 5 mg of DOX-IR820-PGMD NPs were resuspended in 3 mL of 0.01 M PBS
(pH=7.4 or pH=5.0). Next, the sample was divided equally into three Eppendorf tubes,
which were shaken at 35 rpm at 37°C in an incubator. The tubes were then removed from
the incubator every hour up to the first 5 hours, and then after 24 hours. Each time, the
samples were centrifuged at 14,000 rpm for 30 minutes. Following this, the supernatant
was collected in 4.5-mL cuvettes, and the DOX and IR820 content were estimated using
a spectrofluorometer (Jobin Yvon Horiba, Edison, NJ). The NPs were again suspended in
fresh PBS solution and incubated for later time release measurements. This process was
repeated at regular time intervals, every 7 days after the first day, for a period of 29 days.
The release of DOX from DOX-IR820-PGMD NPs after exposure to laser in different pH
was also studied. Briefly, the NPs were measured and resuspended in 3 mL PBS with
different pH (pH=7.4 or pH=5.0) to obtain 5 µM IR820. Then, the suspension was
exposed to an 808-nm NIR laser (RLDH808-1200-5, Roithner Laserthchnik, Austria) for
3 minutes with power density of 1440 J/cm2. Finally, the suspension was centrifuged and
processed as previously described.
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3.1.6.2. IR820 release kinetics profile in IR820-PGMD NPs
IR820 release kinetics study followed the protocol described in section. 3.1.6.1. IR820
release measurements in different pH PBS were performed only up to 24 hours because
the fluorescence intensity of IR820 becomes unstable after 24 hours. Also, IR820 release
was not measured after laser exposure to NPs since photobleaching occurs after laser
excitation.
3.1.6.3. DOX cellular uptake experiments
Two cell lines (MES-SA and Dx5) were used to study the cellular uptake of
unencapsulated DOX and IR820 (designated as free DOX + IR820) and compare with the
uptake of the NP formulation. On the first day, the cells were seeded into 24-well plates
at a cell density of 100,000 to 200,000 cells per well. On the second day, the cell medium
was removed, and free DOX + IR820 or DOX-IR820-PGMD NPs in growth medium was
added to the plates at a normalized DOX concentration of 4 μM (2.3 μg/mL). The plates
were then placed back in a cell incubator for 24 hours. The control group means no drug
was added. After 24 hours, the cell medium was removed, and the cells were washed with
ice cold DPBS four times and then lysed with 1 mL of DMSO. The supernatants were
centrifuged at 14,000 rpm for 10 minutes and collected to obtain cell lysates. The DOX
fluorescence intensity of cell lysates was measured by a spectrofluorometer (Jobin Yvon
Horiba, NJ) at λex = 482 nm, λem = 590 nm to determine DOX concentration. To adjust
the background fluorescence from cellular components, a DOX calibration curve was
created by dissolving DOX and IR820 in DMSO and adding the solution to untreated
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cells. The protein content in the cell lysates can be measured using a micro BCA protein
assay kit, and the absorption data was acquired at 562 nm with the same
spectrophotometer. Cellular uptake of DOX for different treatments was calculated by
normalizing the DOX amount to the protein amount. An average value was obtained from
three wells in each treatment for each experiment, and an average (± SD) intracellular
uptake of DOX from three experiments was plotted.
3.1.6.4. Subcellular localization
To study the intracellular localization of free IR820, IR820-PGMD NPs and DOXIR820-PGMD NPs, cells were seeded with a density of 4 × 104 cells per well inside wells
of a 24-well tissue culture plate, and incubated overnight to reach confluence. On the
second day, cell medium was removed and then replaced with 0.5 mL of 5 µM IR820,
0.05 mg/mL IR820-PGMD NPs (5 μM IR820) and 0.05 mg/mL DOX-IR820-PGMD NPs
(4 μM DOX plus 5 μM IR820). The plates were kept in a 37°C incubator for 24 hours
and protected from light exposure. After incubation, cells were washed with PBS three
times and fixed with 4% (vol/vol) formaldehyde. Then, the specimens were observed by
fluorescence microscopy (Olympus IX81, Japan) with a 20X objective or 60X water
merged objective. The fluorescence was imaged at λex (490 nm), λem (580 nm) for
DOX, λex (775 nm), λem (845 nm) for IR820. A CCD camera was used to capture the
signals and the images were software-merged with pseudo color (IPLab, Qimaging,
Canada).
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For the subcellular localization study of free IR820 and IR820-PGMD NPs. The images
were recorded at the same exposure time for both of the treatments in SKOV-3. The
acquired fluorescence images were processed by Matlab (MathWorks, Massachusetts) to
calculate the image ratio R. First, the intensity of each pixel was background image
subtracted, and a region of interest was defined as being composed of any pixels with
above-background intensity values (defined as an intensity of at least 2 out of a 255 scale
after background subtraction). Background cell images were taken without turning on the
fluorescence lamp. The ratio R was then determined by normalizing the total pixel
intensity of this region of interest to its total area.
Lysotracker Blue (Invitrogen, NY) and SKOV-3 were used to identify the subcellular
localization of IR820-PGMD NPs with λex (355 nm), λem (420 nm). SKOV-3 cancer
cells wereused because of their larger size compared to MES-SA and Dx5, which makes
it easier to identify the localization of Lysotracker Blue. All the subcellular localization
experiments were carried out as described before, with the addition of 5 µM Lysotracker
Blue to SKOV-3 at the end of the treatment and incubation with cells for 5 minutes.
3.1.6.5.Cytotoxicity assessment
Cell viability was measured with the sulforhodamine B (SRB) assay (Invitrogen, NY),
which colorimetrically measures cellular protein. In this study, the cytotoxicity of nine
different treatments (laser only group, free IR820, free DOX plus IR820, IR820-PGMD
NPs, DOX-IR820-PGMD NPs, IR820 w/ laser, free DOX plus IR820 w/ laser, IR820PGMD NPs w/ laser, DOX-IR820-PGMD NPs w/ laser) were investigated. The detailed
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procedure is the same as we have described in our previous paper (55). Briefly, cells were
seeded in a 96-well plate on the first day, and after overnight incubation they were
exposed to different treatments. The cytotoxicity was measured with the SRB assay 24
hours post treatment. Tested DOX and IR820 concentrations were at 5 μM. We also
tested the cytotoxicity of void PGMD NPs at higher concentrations (0.1 mg/mL) than
those used in the experiment (0.05 mg/mL). An average value was obtained from four
wells in each treatment for each experiment. Then, an average (± SD) “cell growth” from
three experiments was plotted against increasing DOX and IR820 concentrations. Cell
growth values were generated by normalizing the data from each treatment to the control
values, which did not receive any treatments. Cell growth was calculated by the
following formulas: (Tx−To)/(C−To) * 100 if Tx>To, and (Tx−To)/To * 100 if Tx<To.
SRB value To is defined as the initial amount of cells; Tx corresponds to the treatment
values; C is SRB value from the controls, which did not receive any treatments. Cell
growth was plotted against DOX concentration to show toxicity effects as described by
Monks et al. (111) and also used previously by our group (55). If Tx>To, the treatment is
considered as growth inhibition; if Tx<To, there is no net cell growth after the treatment,
so its effect is considered as cell killing. Statistical significance for sample means of cell
net growth among treatment groups at the same DOX concentration was identified by
one-way analysis of variance (ANOVA).
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3.2.

The fulfillment of Specific Aim 2

All the assays were carried out in the following groups:
NIR laser-IR820 HT delivery system and incubator HT delivery system, which were
described in section 3.1.3. and 3.1.4.
3.2.1. Study of ROS expression
Intracellular ROS levels was measured using the fluorescent dye 5-(and-6)-chloromethyl2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) (Invitrogen,
NY), which was converted into a nonfluorescent derivative (H2DCF) through cellular
esterases after uptake by cells. Then, H2DCF can be oxidized to 2′,7′-dichlorofluorescein
(DCF), which is highly fluorescent in the presence of ROS. Since this assay requires
fluorescence measurements with excitation around 490 nm, which overlaps with the
absorption spectrum of DOX, IR820-PGMD NPs were used to measure ROS expression
in cancer cells. After HT (either 1-hour incubator HT or 3-minutes NIR-laser induced
HT), cells were washed with PBS and collected by incubating briefly with trypsin. The
same number of cells were counted and incubated with CM-H2DCFDA at 37 °C with 5%
CO2 in the dark. After 30 min, cells were briefly washed with PBS, and the intensity of
DCF was measured by flow cytometer (BD Accuri C6, NJ).
3.2.2. Study of HIF-1 expression
To investigate HIF-1 expression in both incubator HT and laser/Dye/NP HT,
human/mouse Enzyme-Linked ImmunoSorbent Assay (ELISA) was used to detect the
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expression of HIF-1 using HIF-1α antigen. Basal level HIF-1 expression was identified in
cells incubated at normal temperature (37°C). HIF-1 expression was measured
immediately after HT by reading the plate using a fluorescence plate reader (GENios,
TECAN, CA) with excitation at 540 nm and emission at 600 nm to measure the amount
of total HIF-1 in the cells. Then the plate was read with excitation at 360 nm and
emission at 450 nm to measure the amount of total cytochrome c in the cells. In the end,
the HIF-1 amount was normalized to the amount of cytochrome c and expressed as HIF-1
activity.
3.2.3. Study of VEGF expression
Cancer cell culture medium was collected 6 hours after HT. After centrifuging cell
culture media for 10 minutes at 16,000 × g, 200 µL of supernatant was added into a 96well plate provided in a human quantikine VEGF ELISA kit. VEGF levels were
quantified following VEGF ELISA kit protocol and SRB assay was used to determine the
amount of cellular protein in each well. Finally, the measured VEGF amount was
normalized to SRB value and the calculated results were normalized to controls.
3.2.4. Cytotoxicity after HT treatment
Two different heating modalities, including both the incubator and laser/Dye/NP HT
delivery system, were used for in vitro Cytotoxicity studies. Detailed descriptions of the
heating systems and the temperature calibration for both heating modalities were
discussed before in sections 3.1.3. and 3.1.4. Note that when incubator HT was used,
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cells were incubated with the same concentration of IR820-PGMD NPs as used in
laser/Dye/NP HT in order to eliminate the effect of NPs by themselves.

3.3. The fulfillment of Specific Aim 3
3.3.1. Mice models
Thirty-six Nd4 Swiss Webster mice (25–30 grams, 9 weeks old) were purchased from
Harlan (Indianapolis, IN), kept under standard housing conditions, and fed ad libitum. All
protocols followed the regulations of the Institutional Animal Care and Use Committee.
Mice were randomly assigned to different experimental groups based on different time
points, namely 15 minutes, 30 minutes, 60 minutes, and 24 hours. On the day of the
experiment, the animals were anesthetized and injected through the tail vein with a
solution of NPs in PBS. The concentration of injected NPs was determined based on an
IR820 dose of 0.24 mg/kg of body weight and an injection volume of 0.2 mL. The choice
of 0.24 mg/kg was based on the work of Rajagopalan et al., who used a 0.24 mg/kg dose
of ICG to study its pharmacokinetics in mouse blood (112). Our group subsequently also
utilized this dose in rat and mice studies of free ICG and free IR820 biodistribution (79).
The choice of 0.2 mL was based on reported safe intravenous (i.v.) injection volumes for
mice (113). Therefore, to calculate the amount of free dye/NPs we need to use for animal
studies:
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For free dye:
Injection mass= mouse weight in kg * 0.24

Free dye solution concentration=

mg
kg

injection mass
0.2 mL

For NPs, we need to introduce one more term as IR820 loading to 0.24 mg dye/kg dose:
Injection mass= mouse weight in kg * 0.24
NPs solution concentration=

mg
kg

/(

mg dye
mg NPs

)

injection mass
0.2 mL

Free dye and NPs were first resuspended in DI water or DPBS to reach the final desired
concentration and NPs solution was sonicated to make sure they resuspended properly.
Then, 0.2 mL of the solution was drawn into a 1-mL syringe with a 30g needle, and the
syringe covered with aluminum foil to protect the drug from light. Before the injection,
an infrared lamp was used to warm the mouse and facilitate the injection process by
dilating the tail veins.
3.3.2. NIR in vivo biodistribution imaging
To study the biodistribution, we used an imaging system consisting of a Sanyo DL 7140201S laser (80 mW, 785 nm) and a Retiga CCD camera (Qimaging, Canada) coupled
with NIR filter (λex=785 nm, λem=820 nm). The entire setup was covered by BK5
blackout material during the experiment. On the day of the experiment, the mice were
first anesthetized by inhalation of isoflurane in a closed chamber, and then injected
intraperitoneally (i.p.) with pentobarbital. Animals in the 15-minute group received a 100
mg/kg pentobarbital dose. Animals in the 30-minute and 60-minute time groups, received
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the same 100 mg/kg dose, but administered as two half-doses. The first 50 mg/kg were
given before dye injection and imaging, and the additional 50 mg/kg were given 15
minutes before the terminal time point in order to reach euthanasia levels. This split
administration protocol was used to ensure that the animals would not die before the
terminal time point. In the case of the 24-hour group, the animals received a 40 mg/kg
pentobarbital dose on the first day of imaging, were returned to their cage for 24 hours,
and received a 100 mg/kg pentobarbital dose before 24-hour imaging.

For all groups, after the administration of pentobarbital, mice were placed on the imaging
stage and a white light image was acquired with white light illumination to determine the
position of the mouse. Then, the laser was turned on with white light off to obtain a black
image as the background prior to dye injection. Laser current was set to 60 mA for
acquiring optimal fluorescence signal. The exposure time of the images was 10 seconds
and threshold gain was 3. The camera started recording immediately after the injection. A
series of images was taken using QCapture Pro software over at least 40 minutes. In the
24-hour group, one white image and one fluorescent image were taken under the same
operating conditions 24 hours after the i.v. injection of dye or NPs. After the 24-hour
imaging protocol was completed, the animal was euthanized by removal of the heart
while under deep anesthesia, and organs were carefully dissected. The lungs, kidneys,
liver and intestines were then placed in black-coated Petri dishes and imaged using the
same imaging setup. Later, the images were processed with Matlab to calculate the image
fluorescence intensity R as described before in section 3.1.6.4.
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3.3.3. Pharmacokinetics and biodistribution study
3.3.3.1.Study Design
Thirty-six healthy Nd4 Swiss Webster mice were divided randomly to different groups
with different treatments as shown in Table 3.
Treatments

15 minutes

30 minutes

60 minutes

24 hours

Free IR820
IR820-PGMD NPs
DOX-IR820-PGMD NPs

Group 1
Group 2
Group 3

Group 4
Group 5
Group 6

Group 7
Group 8
Group 9

Group 10
Group 11
Group 12

Table 3. Study design for biodistribution experiments of IR820, IR820-PGMD NPs, and
DOX-IR820-PGMD NPs. Each group has three mice.
3.3.3.2.Pharmacokinetics study
At the terminal time point for all groups (15min, 30min, 60min, and 24h), plasma
samples were collected in order to study the pharmacokinetic profiles of IR820 and DOX
after imaging. Plasma samples were obtained by heart puncture followed by
centrifugation 2x for 3 minutes at 12,000 rpm. Plasma samples were then incubated in
DMSO (1:50 volume ratio plasma: DMSO) for thirty minutes and centrifuged again at
6,000 rpm for 15 minutes. The supernatant was used to perform spectrofluorometric
measurements of dye content using previously created calibration curves of IR820 in
DMSO at 785 nm excitation, and DOX in DMSO at 482 nm. The in vivo behavior of the
drug/dye can be estimated based on different models, which are based on the assumption
that the drug/dye are distributed into one or more so called “compartments”, such as
organs or body fluids etc. (114). The commonly used model assumes there are input
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(drug/dye administration), mass transfer in compartments, and output (drug clearance)
(115).
The one compartment model is the simplest model, which assumes the drug/dye is
distributed in the body uniformly and gets eliminated either by metabolism or excretion
in urine and feces (115). The equation used to describe the one compartment model is
listed below and assumes the molecule follows a monoexponential decay.
C(t)=C0 × e-kt

(Equation 3)

C(t) is the concentration as a function of time, C0 is the initial concentration, k is the
clearance rate, and t is time. Following this equation, the half-life of the molecule,
defined as the amount of time it takes for 50% of the agent to disappear from the system,
is calculated by Equation (4):
t1/2 =

ln (2)
k

(Equation 4)

A two-compartment model can also be used to estimate the drug/dye in vivo behavior.
The assumption of a two-compartment model is that there is central compartment,
comprised of the plasma and well-vascularized organs such as the liver; and then the
peripheral compartment, which encompasses the rest of the organism. Molecules injected
into the system will undergo two distinct processes or phases. In the first phase,
distribution, mass transfer occurs from the central compartment to the peripheral
compartment until steady state is reached (114). In the subsequent second phase,
elimination, the concentration gradient reverses and mass transfer occurs from the
peripheral to the central compartment. The mass transfer between peripheral and central
compartment will continue during the elimination process until the molecule is cleared
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from the body by liver metabolism and kidney excretion (115, 116). Therefore, the
equation for a two-compartment model is the bi-exponential decay equation in Equation
(5):

C t =A×e-at +B×e-bt

(Equation 5)

where C(t) is the concentration as a function of time; A and B are constants for the
distribution and elimination process, respectively; a is the rate constant for distribution
and b is the rate constant for elimination; t is time (115). Therefore, the model has been
separated into two parts: initial rapid decay phase for distribution and second -slow
declining phase for elimination. At the starting point (t=0), the sum of A and B is equal to
the initial drug/dye concentration.
The distribution process half-life can be calculated as:
t1/2 =

ln 2
a

(Equation 6)

And the elimination process half-life can be calculated as:
t1/2 =

ln 2
b

(Equation 7)

The choice of the compartmental model is usually based on the a priori prediction of
drug/dye in vivo behavior, the goodness of fit between data and model, and the
improvement in fit, if any, after using a higher order model.
3.3.3.3.Pharmacokinetic analysis of plasma data
In order to estimate the initial injection dose amount, we first calculated the average
weight of all the mice and obtain an average weight of 25 grams. Then, the initial dose
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amount can be calculated as approximately 6 µg IR820 based on the 0.24 mg/kg injection
dosage. The ratio of plasma volume to body weight is 58.5 mL plasma/kg body weight
given by the literature (117), so we assumed a 25-g mouse has plasma volume
approximately 1.5 mL. Thus, the initial dose concentration can be calculated to be
approximately 4 µg dye/mL in plasma. Using five data points (0min, 15min, 30min,
60min, 24h) and the fit curve toolbox of Sigmaplot (Systat Software, San Jose, CA), we
can predict the drug/dye physiology decay behavior with monoexponential or
biexponential model. Since there is no study in the literature investigating the IR820 in
vivo distribution and elimination behavior, we attempted to generate an in vivo model
starting from the simplest model. Moreover, IR820 has similar characteristics as ICG,
and ICG pharmacokinetics had been studied via both one-compartment and twocompartment model approaches (118). Hence, we started with the simplest
monoexponential model and then the biexponential model to determine which model to
be used based on the goodness of the experimental data fit to the models used. For DOX
pharmacokinetics, there are also studies using both one-compartment and twocompartment models (119-121), and we also chose the model based on the goodness of
fit. As a result, the overall half-life (if one-compartment was used), or the distribution
half-life and elimination half-life (if two-compartment was used) can be calculated based
on the equations given above. Following the determination of half-lives, we also
calculated other pharmacokinetic parameters: the area under the pharmacokinetic curve,
the mean plasma residence time, and the clearance rate.
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The area under the curve (AUC) is the integral of drug/dye concentration vs. time curve,
which can be calculated by Simpson’s rule.
Area under the curve (AUC)=

∞
C(t)dt
0

(Equation 8)

The mean residence time in plasma (tp) is the average time spent by the drug/dye in
plasma, and is given by:
tp =

AUC
C0

(Equation 9)

where C0 is the model original concentration.
The total body clearance rate (CL) (volume of drug/dye cleared from the body vs. time) is
given by:
CL=

Dose
AUC

(Equation 10)

Based on the preceding calculations, we compared free IR820, IR820-PGMD NPs and
DOX-IR820-PGMD NPs pharmacokinetic parameters using one-way ANOVA (p<0.05).
3.3.3.4. Quantitative measurement of organ content
In addition to plasma measurements, in the 24h group the liver, lungs, kidneys, and
intestines were also extracted. The quantitative measurements of IR820 content in
different organs after 24 hours were performed by dye extraction in DMSO following the
procedures described by Saxena et al. for ICG (122) and used by us previously (79).
Briefly, the dissected organs (liver, lungs, kidneys, and intestines) were collected and
homogenized. Then, the homogenized tissues were incubated with 5 mL DMSO for at
least 4 hours to allow the IR820 and DOX to be dissolved. Then, the supernatant was
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collected and centrifuged at 6,000 rpm for 15 minutes. Next, the fluorescence intensity of
the supernatant was measured as described above for measuring plasma in section
3.3.3.2., and the fluorescence intensity was converted to drug/dye concentration in
DMSO (µg/mL). Finally, dye mass in μg obtained from this measurement was
normalized to homogenized organ mass in grams.
3.4. Statistical significance
Statistical significance was identified by ANOVA or t-test (SPSS, Chicago, Illinois) for
the difference among treatment groups and control groups. A p-value < 0.05 was
considered to be statistically significant.
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CHAPTER 4: RESULTS
4.1. Results accomplished for Specific Aim 1
4.1.1. Characterization of PGMD polymer
The PGMD polymer has a glass transitional (Tg) temperature of 42.2°C, measured by
DSC. The Tg (~42°C) of PGMD polymer allowed an increased drug release with
exposure of the NPs to an external heat stimulus. The MW measured by GPC column is
around 3000 Da. The Fourier transform infra-red spectra (FTIR) showed an intense C=O
stretch at 1735 cm-1, indicating the appearance of a typical esteric bond (Figure 1).

Figure 1. FTIR spectrum shows the appearance of a C=O stretch at 1735 cm−1, typical of
ester bonds.
4.1.2. Characterization of void PGMD NPs, IR820-PGMD NPs and DOX-IR820PGMD NPs.
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The size, zeta potential, polydispersity (PDI), and drug loading efficiency for void
PGMD NPs, IR820-PGMD NPs and DOX-IR820-PGMD NPs are shown in Table 4. The
size and shape of void PGMD NPs are also given in DLS measurement (Figure 2), and
SEM (Figure 3).
Formulation

Size
(nm)

Polydispersity Zeta
(PDI)
potential
(mV)

IR820
loading
(w/w %)

DOX
loading
(w/w %)

PGMD void NPs

92± 19.6

0.095±0.015

-34.3±1.6

N/A

N/A

IR820-PGMD
NPs

109±8.2

0.151±0.006

-29.1±7.5

8.4±0.5

N/A

DOX-IR820PGMDNPs

125±19.7 0.182±0.023

-20.3±2.9

8.1±0.6

4.3±0.3

Table 4. Mean size, PDI, zeta potential, and percent of loading efficiencies for void
PGMD NPs, IR820-PGMD NPs, and DOX-IR820-PGMD NPs (n = 8).
The NPs are between 50-200 nm range, which can potentially avoid premature clearance
by the RES.
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Figure 2. (A) DLS measurement of void PGMD NPs; (B) DLS measurement of IR820PGMD NPs; and (C) DLS measurement of DOX-IR820-PGMD NPs.
The SEM image was used to confirm the size and shape of void PGMD NPs and it
showed that void PGMD NPs were nearly spherical and uniformly distributed.

Figure 3. SEM image of void PGMD NPs.
4.1.3. Heating modalities
4.1.3.1. Incubator HT delivery system and temperature increase profile
Temperature calibration studies were carried out to find the temperature profile of the
fluid inside the wells of 96-well plates as shown in Figure 4. The temperature increased
in incubator HT is very slow, taking approximately 45 minutes to reach 42°C.
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Figure 4. Temperature curve during 1 hour incubator HT.
4.1.3.2. Laser-IR820-PGMD NPs HT delivery system and temperature increase profile
The temperature profile of IR820-PGMD NPs is shown in Figure 5. We used different
concentrations of IR820-PGMD NPs in order to find out the optimal concentration which
could induce a temperature increase to between 41°C~45°C. As shown in Figure 5, 0.05
mg/mL IR820-PGMD NPs, which has 5 µM IR820, can elevate the temperature to
approximately 42°C. Since this temperature is very close to Tg of PGMD polymer and it
is sufficient to induce HT effect to cancer cells, we chose to perform our studies based on
0.05 mg/mL IR820-PGMD NPs/DOX-IR820-PGMD NPs.
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Figure 5. Temperature profile during 3 minutes laser exposure of different concentration
of IR820-PGMD NPs. Experiments were repeated 3 times.
4.1.4. Thermal dose calculation
A much slower temperature increased was observed in incubator HT compared to the
temperature increase in laser/Dye/NP exposure. Thermal doses given in these two
treatments were calculated based on the CEM43 model developed by Sapareto et al. (110)
as described before. We made a slight modification to use the model at 42°C (CEM42)
with a smaller empirical value R=0.25. As shown in Table 5, laser/Dye/NP HT for 3
minutes with 5 µM IR820-PGMD NPs produced a much lower thermal dose as compared
to the 42°C incubator HT treatment for 1 hour.
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Treatment type

CEM42 (min)

5 µM IR820-PGMD NPs + 3min laser

3.06

5 µM IR820-PGMD NPs + 42°C incubator 1h

25.98

Table 5. Calculated CEM42 in different types of HT treatment, based on the temperature
curves in Figures 4 and 5 and using Equations 1 and 2.
4.1.5. The in vitro studies of void PGMD NPs, IR820-PGMD NPs and DOX-IR820PGMD NPs
4.1.5.1. In vitro drug release
The release kinetics profile of DOX from DOX-IR820-PGMD NPs is shown in Figure 6.
In pH 7.4 PBS, the burst release of DOX was around 49% in the first 5 hours, followed
by a slow release reaching a total of only ~52% after 29 days. When these NPs are
exposed to the laser for 3 minutes in pH 7.4 PBS at the beginning of the experiment, 5
µM IR820 is able to increase temperature to approximately 42°C, inducing a rapid
release of ~81% DOX in 5 hours and 85% in 29 days. Additionally, an acidic
environment (pH=5.0) can also induce the release of DOX from the NPs to up to ~72% in
5 hours and 86% in 29 days. DOX release was further enhanced when the NPs were
placed in acidic buffer and exposed to laser for 3 minutes. Overall, ~90% DOX was
released in 5 hours and ~95% in 29 days. We observed a very slow release of DOX after
the initial burst release from NPs in the absence of an external stimulus. However, either
acidic buffer or heat can induce the release of DOX, indicating that PGMD NPs are
thermal sensitive and pH sensitive.
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Figure 6. Cumulative percent release of DOX from DOX-IR820-PGMD NPs under
different experimental conditions.
The release of IR820 from DOX-IR820-PGMD NPs is shown in Figure 7. IR820 release
was also enhanced when NPs were placed in an acidic environment. Approximately 48%
IR820 was released in 5 hours in acidic PBS (pH=5.0), and up to 52% IR820 was
released in 24 hours. Since the PGMD NPs are pH sensitive, it was expected that an
acidic environment would induce higher amount of IR820 release from NPs as compared
to a neutral environment (pH=7.4). IR820 measurements were performed only up to 24
hours because the fluorescence intensity of IR820 becomes unstable after 24 hours. Also,
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IR820 release was not measured after laser exposure to NPs since photobleaching occurs
after laser excitation.

Figure 7. Cumulative percent release of IR820 from DOX-IR820-PGMD NPs under
different experimental conditions.
4.1.5.2.DOX cellular uptake experiments
The cellular uptake results are consistent with the literature in that free DOX is taken up
by cells mainly through diffusion (123), while the NPs formulation is generally delivered
into cells by endocytosis (124). An improved DOX cellular uptake profile by NPs was
observed as compared to their free form in the MDR cell line Dx5 as shown in Figure 8,
probably due to reduced elimination of drug with NPs delivery since NPs formulation can
overcome the P-gp effect. However, NPs did not result in greater DOX uptake in drug-
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sensitive cancer cell line MES-SA compared to the free drug form, since these cells do
not have mechanisms to affect drug retention.

Figure 8. 24-hour intracellular DOX uptake in MES-SA and Dx5 cells; n=3 experiments,
3 wells per treatment. * P<0.05 (by t-test) between NP formulation and NP free form for
each cell line, indicating significant differences due to loading of DOX into PGMD NPs.
4.1.5.3.Subcellular localization
Subcellular localization of 5 µM free IR820 and 0.05 mg/mL IR820-PGMD NPs
(equivalent to 5 µM IR820) is shown in Figure 9. The subcellular localization of both
treatments is similar. Free IR820 possibly binds to cytoplasmic proteins such as ligandin
(125), leading to widespread cytoplasmic localization. In the case of the NP formulation,
IR820 released from the NPs will behave the same as free IR820, whereas IR820 still
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within the NPs will be located in endosomes/lysosomes. Images from three different
experiments of free dye and NPs treatments were chosen for statistical studies for
fluorescence intensity (n=3) and the R values from the fluorescence microscope images
show that the NP formulation produces a higher intracellular fluorescence intensity
(R=3.75±0.54) than does the free dye (R=2.89±0.23) after 24 hours of incubation,
although the difference is not statistically significant, possibly due to the small sample
size (n=3 for each group).

Figure 9. Subcellular localization of free IR820 and IR820-PGMD NPs in SKOV-3
cells. All images were taken with 60X water-merged objective after 24 hours
incubation of NPs with cells and merged with pseudo color by software. A. IR820
fluorescence of free IR820; B. IR820 fluorescence of IR820-PGMD NPs. Scale bar
represents 20 µm.
IR820-PGMD NP subcellular localization images are shown in Figure 10. In Figure 10A,
Lysotracker Blue was used to stain SKOV-3 lysosomes, while Figure 10B shows the
fluorescence of IR820. Figure 10C, which is the merged image, shows that PGMD NPs
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are mainly localized in the lysosomes as indicated by the overlap with the Lysotracker
Blue. This result indicated that most PGMD NPs were probably taken up into cells by
endocytosis. However, further studies are needed to investigate the specific endocytic
pathways used by the cells.

Figure 10. Subcellular localization of IR820-PGMD NPs in SKOV-3. All the images were
taken after 24 hours incubation of NPs with cells and merged with pseudo color by
software (IPLab, Qimaging). A. Lysotracker Blue fluorescence; B. IR820 fluorescence of
IR820-PGMD NPs; C. merged picture of A and B; D. phase contrast image. Scale bar
represents 20 µm.
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As seen in Figure 11A, we observed that some DOX molecules were located in the
nucleus. Since the free drug accumulates in the nucleus, we would expect the same fate
for DOX leaked out from NPs (74). On the other hand, DOX molecules that remained in
the NPs stayed in the cytosol because size limitations prevent the NPs from crossing the
nuclear pore complex. In Figure 11B, we can see that IR820 stayed in the cytosol for both
the free form and the molecules that were in NP form. Free form localization is due to the
possible binding of free IR820 to cytoplasmic proteins such as ligandin (126). In the
merged picture shown in Figure 11C, the yellow bright dots in the cytosol indicate that
the NPs are still in the process of releasing DOX and IR820.
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Figure 11. Subcellular localization of DOX-IR820-PGMD NPs in SKOV-3 cells after 24h
incubation. A. DOX fluorescence of DOX-IR820-PGMD NPs; B. IR820 fluorescence of
DOX-IR820-PGMD NPs; C. merged picture of A and B; D. phase contrast image. The
concentrations of IR820 and DOX were kept at 5 μM and 4 μM, respectively. Scale bar
represents 20 µm.
4.1.5.4. In vitro cytotoxicity
4.1.5.4.1. Void PGMD NPs cytotoxicity profile
Void PGMD NPs cytotoxicity profile is shown in Figure 12. We tested the NP
concentration up to 0.1 mg/mL in both MES-SA and Dx5 cells and no toxicity was
observed in either cell line. The desired NPs concentration (0.05 mg/mL) is based on the
DOX and IR820 loading result, which is in the safe range of using PGMD NPs.
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Figure 12. 24-hour cytotoxicity profile of void PGMD NPs in MES-SA and Dx5.

62

4.1.5.4.2. Cytotoxicity of IR820-PGMD NPs
Figure 13 shows the cytotoxicity of IR820-PGMD NPs in MES-SA and Dx5 in different
concentrations. It is shown that IR820-PGMD NPs does not cause any toxicity effect in
SKOV-3 and Dx5 cells at 0.05 mg/mL (5 µM IR820), whereas it results in approximately
15% cell growth inhibition in MES-SA. This is probably because the fact that MES-SA
cells are more sensitive to environmental stressors than SKOV-3 and Dx5. The same
phenomena was observed when 5 µM free IR820 was incubated with MES-SA cells in
our previous study (79).
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Figure 13. Cytotoxicity of IR820-PGMD NPs.
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4.1.5.4.3. Cytotoxicity of IR820-PGMD NPs, DOX-IR820-PGMD NPs with exposure
to laser as compared to free IR820 and free DOX + IR820
MES-SA and Dx5 cell proliferation following IR820-PGMD NPs, free IR820, DOXIR820-PGMD NPs, and free DOX + IR820 incubation w/ or w/o laser exposure is shown
in Figure 14. A solution of 0.05 mg/mL IR820-PGMD NPs or DOX-IR820-PGMD NPs
(containing approximately 5 μM IR820) can increase the temperature from a baseline of
37°C to 42°C following exposure to an 808 nm NIR laser (power density is 1440 J/cm2)
for 3 minutes, as shown above. Based on this finding, we used a concentration of 0.05
mg/mL IR820-PGMD NPs/DOX-IR820-PGMD NPs in our study and compared them to
free IR820/ free DOX + IR820 treatment. Both NP formulations and the free agent
treatments produced significant cancer cell killing after laser exposure compared to the
no-laser group due to the HT effect. It is important to note that laser treatment by itself
does not have an effect on cell growth.
Our results showed that, although IR820-PGMD NPs seems to have higher cytotoxicity
than free IR820 after laser exposure in MES-SA, the difference did not reach statistical
significance. The same phenomena were observed in DOX-IR820-PGMD NPs compared
to free DOX + free IR820 in MES-SA cells without laser exposure, and the difference in
cancer cell killing is not statistically significant either. On the other hand, IR820-PGMD
NPs and DOX-IR820-PGMD NPs showed much higher cytotoxicity than free IR820 or
DOX-IR820 treatment in Dx5, and the difference is statistically significant (p<0.05).

64

Additionally, the combination of HT and chemotherapy caused enhanced cancer cell
killing in both cell lines compared to either chemotherapy or HT alone (p<0.05). Based
on our results, the treatment of the resistant Dx5 cells with NPs containing 4 μM DOX
and 3 minutes of laser exposure can improve the cytotoxicity and the cell killing effect to
reach levels comparable to those observed in DOX-sensitive MES-SA cells.

Figure 14. 24-hour cytotoxicity profile of NPs, free IR820 or free IR820 +free DOX w/
or w/o 3 minutes laser exposure in MES-SA and Dx5 cells; n=3, 4 wells/treatment. *
P<0.05 (by ANOVA) indicates significant differences in cytotoxicity between free agent
treatment and NPs groups in Dx5 due to the bypassing of P-gp; and ** P<0.05 (by
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ANOVA) indicates significant differences in cytotoxicity between laser-treated and nolaser-treated groups due to HT enhancement of cancer cell killing.
4.2. Result accomplished for Specific Aim 2
4.2.1. Cellular response after laser/Dye/NP HT and incubator HT
4.2.1.1. ROS production after HT treatment
ROS production after two different types of HT is shown in Figure 15. Incubator HT at
42°C for 1h induced production of ROS in both MES-SA and Dx5 cells, whereas ROS
production after 3 minutes of 5 μM laser/Dye/NP HT was not different from the control
cells that were incubated in a 37°C incubator.

Figure 15. Laser/Dye/NP and incubator HT-induced ROS production were measured in
MES-SA and Dx5 cells. Fluorescent dye CM-H2DCFDA was used to measure the
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fluorescence intensity and they were normalized to values obtained from the control
group (37°C). *P < 0.05 indicates significant ROS production was observed in incubator
induced-HT as compared to control. Laser/Dye/NP induced-HT did not result in
enhanced ROS production as compared to control (mean ± SD, n = 3).
4.2.1.2. HIF-1 expression
As expected, incubator HT induced significantly elevated HIF-1 expression as compared
to control (p<0.05), while laser/Dye/NP HT did not result in significant changes in HIF-1
expression. These results suggest that rapid laser/Dye/NP HT, with a much lower thermal
dose, did not up-regulate HIF-1 expression.

Figure 16. Laser/Dye/NP and incubator HT-induced HIF-1 expression were measured in
MES-SA and Dx5 cells. HIF-1 activity was assayed using HIF-1 ELISA. All the values
measured were normalized to the mean value of the treatment at 37°C. *P < 0.05
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indicates significant HIF-1 expression was observed in incubator induced-HT as
compared to control. Laser/Dye/NP induced-HT did not result in promoted HIF-1
expression as compared to control (mean ± SD, n = 3).
4.2.1.3. VEGF expression
VEGF expression is shown in Figure 17. It is not surprising to observe that VEGF
secretion was enhanced after incubator HT, since HIF-1 expression was elevated after
incubator HT and VEGF is one of the downstream target genes of HIF-1. Accordingly,
we did not observed significant changes in VEGF expression after laser/Dye/NP HT,
given that laser/Dye/NP HT did not have any effect on HIF-1 expression.

Figure 17. Laser/Dye/NP and incubator HT-induced VEGF expression were measured in
MES-SA and Dx5 cells. VEGF secretion was measured using VEGF ELISA. The obtained
VEGF expression amount was normalized to SRB value as an indicator of cellular
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protein amount. All the values measured were then normalized to the controls. *P < 0.05
indicates significant VEGF expression was observed in incubator HT as compared to
control. Laser/Dye/NP HT did not result in enhanced VEGF expression (mean ± SD, n =
3).
4.2.2. Cytotoxicity study
The laser/Dye/NP HT system described above was used for the cytotoxicity study.
Significant cancer cell killing was achieved after exposure of IR820-PGMD NPs to this
laser system. As shown in Figure 18, both incubator HT and laser/Dye/NP induced HT
significantly killed cancer cells due to the HT effect (p<0.05). Laser/Dye/NP HT
significantly kills cancer cells better compared to incubator HT (p<0.05) probably due to
the thermotolerance and cell protective mechanisms not being initiated in the latter group
(106).
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Figure 18. 24 hours cytotoxicity profile of IR820-PGMD NPs with laser and incubator
exposure in MES-SA and Dx5 cells; n=3, 4 wells/treatment. * P<0.05 (by ANOVA)
between laser/Dye/NP HT and incubator/NP HT, indicating laser/Dye/NP HT results in
significantly improved cytotoxicity compared to incubator HT. ** P<0.05 (by ANOVA)
between HT groups and without HT group in both cell lines, indicating significantly
higher cancer cell killing was achieved due to HT.
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4.3. Results accomplished for Specific Aim 3
4.3.1. Biodistribution and pharmacokinetic studies of IR820-PGMD NPs and DOXIR820-PGMD NPs
4.3.1.1. In vivo optical imaging
In vivo imaging was performed for all the time points mentioned in the Methodology
section. The images taken at 15min and 24h are shown in Figures 19. These images show
that the biodistribution of IR820-PGMD NPs and DOX-IR820-PGMD NPs are initially
very similar to free IR820, as both appear to be processed rapidly though hepatobiliary
excretion accumulating in the liver within the first 15 minutes. After 24 hours, it seems
that both free dye and NPs mainly locate in the liver and the organ studies showed that
considerable IR820 content were also found in the kidney and the lungs, indicating
uptake by RES. Image ratio R was calculate and given in Table 6, showing that NPs
resulted in significantly higher IR820 fluorescence intensity than free IR820 24h after
injection (p<0.05). Note that the image ratio R is only a measurement of normalized
image intensity per pixel and cannot be used to quantitatively determine in vivo IR820
concentration.
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Figure 19. In vivo imaging of free IR820, IR820-PGMD NPs, and DOX-IR820-PGMD
NPs. (A)-(C) 15min in vivo imaging. (D)-(F) 24h in vivo imaging.
Treatments

R15min

R24h

Free IR820

1.97±0.47

1.42±0.19

IR820-PGMD NPs

2.20±0.50

*2.37±0.62

DOX-IR820-PGMD NPs

1.88±0.54

*2.12±0.57

Table 6. Image ratio R was calculated from fluorescence images of free IR820 and
IR820-PGMD NPs treatments (n=3). * P<0.05 indicates significant higher fluorescence
intensity was observed in NPs as compared to free IR820 24 hours after injection.
4.3.1.2. Pharmacokinetics studies
The pharmacokinetics study of IR820 concentration in plasma at different time points
after injection is shown in Table 7. The quantitative dye content analysis showed that
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IR820 was present in plasma in significantly higher amounts when carried in NPs
compared to free IR820 24 hours after injection (p<0.05).
IR820

IR820-PGMD NPs

DOX-IR820-PGMD NPs

15 minutes

1.94±1.17

3.63±0.20

2.72±0.17

30 minutes

0.97±0.15

0.73±0.25

1.00±0.21

60 minutes

0.34±0.03

0.29±0.02

0.50±0.13

24 hours

0.10±0.01

*0.18±0.05

*0.26±0.06

Table 7. Plasma concentrations (µg/mL) of IR820, IR820-PGMD NPs and DOX-IR820PGMD NPs at different time points after injection. Values represent average±SD (n=3).
* P<0.05, indicates significant difference between both nanoformulations and free IR820
24h after injection.
Based on these results, it seems that NPs have advantages over free dye after initial
distribution, which confirms our hypothesis that PGMD NPs can enhance the dye plasma
residence time. The plasma concentration of DOX-IR820-PGMD NPs is also
significantly higher than free IR820-PGMD NPs after 60min and 24h injection probably
due to their differences in charge.
We also measured the DOX plasma concentration at different time points, the results are
shown in Table 8.
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Time/Treatments DOX-IR820-PGMD NPs
15 minutes

1.69±0.48

30 minutes

1.37±0.16

60 minutes

1.06±0.13

24 hours

0.30±0.09

Table 8. Plasma concentrations (µg/mL) of DOX in DOX-IR820-PGMD NPs at different
time points after injection. Values represent average±SD (n=3).
4.3.1.3.IR820 Pharmacokinetic modeling
As discussed in the Methodology section 3.3.3.3., we assumed the initial plasma IR820
concentration is 4 µg/mL. The IR820 plasma concentration of IR820, IR820-PGMD NPs
and DOX-IR820-PGMD NPs after injection is shown in Figure 20 on a semi-log scale.
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Figure 20. IR820 plasma concentration at different time points after i.v. injection of free
IR820 or IR820 from NPs. The data are expressed in a semi-log scale.
We used both monoexponential and biexponential models to calculate the IR820 plasma
half-life, AUC, mean plasma residence time, etc. The results are shown in Table 9 and
Table 10.
a. One-compartment modeling
Table 9 shows the physiology parameters of IR820, IR820-PGMD NPs and DOX-IR820PGMD NPs calculated based on a one-compartment model.
IR820
Model equation
R2

C(t)=3.984×e-2.805t
0.9971

IR820-PGMD NPs DOX-IR820-PGMD
NPs
-2.132t
C t =4.344×e
C(t)=4.099×e-2.216t
0.8627
0.9674

Table 9. Goodness of fit by using one-compartment model.
From the table above, we can see that the monoexponential model gives a good fit for our
data. The coefficient of determination, denoted R2, is 0.99, 0.86, and 0.97 for IR820,
I820-PGMD NPs, and DOX-IR820-PGMD NPs, respectively. The R2 is not optimal for
IR820-PGMD NPs probably because of the small sample size or experimental error (n=3
for each data point). As more data points are acquired, the better experimental data fit is
estimated.
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b. Two-compartment modeling
Table 10 shows the resulting parameters from a two-compartment modeling approach to
obtain IR820, IR820-PGMD NPs, and DOX-IR820-PGMD NPs data.

Model equation
R2

IR820

IR820-PGMD NPs

C t =3.831×e-3.108t
+0.1702×e-0.02275t
0.9999

C t =2.217×e-2.132t
+2.127×e-2.132t
0.8507

DOX-IR820PGMD NPs
C t =2.066×e-2.216t
+2.033×e-2.216t
0.9524

Table 10. Goodness of fit by using two-compartment model.
We used both monoexponential and biexponential models to estimate free dye and NPs’
physiology parameters. It is shown that R2 was not improved significantly by changing
one-compartment model to two-compartment model for estimation of free IR820
pharmacokinetics, since R2 is already 0.99 with monoexponential model. On the other
hand, R2 for both NP formulations decreased to 0.85 and 0.95 as compared to the onecompartment model, respectively. Therefore, it seems the biexponential model did not
result in improvements for assessment of model accuracy, although the elimination of
IR820 seems to follow a biexponential pattern. This is probably because the goodness of
fit is not very good for IR820 loaded NPs plasma data due to the reason that NPs may
have a different distribution pattern, if we take into account of the IR820 release kinetics
from the NPs. Therefore, we decided to start from the simplest model and use the onecompartment model to calculate all the pharmacokinetics parameters.
Using monoexponential model, we can calculate all the physiology parameters as shown
in Table 11.
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Elimination half-life (hours)
AUC [µg*h/mL]

Free IR820 IR820PGMD NPs
0.25±0.005 0.33±0.022*
1.42±0.028 2.04±0.137*

DOX-IR820PGMD NPs
0.31±0.006*
1.85±0.038*

Mean plasma residence time, tp (h)
Total body clearance rate (mL/h)

0.36±0.007 0.51±0.034*
4.22±0.084 2.94±0.198*

0.46±0.009*
3.24±0.066*

Table 11. Pharmacokinetic parameters calculated based on one-compartment analysis of
dye data in mice. Data represent mean ± S.D. * P<0.05, indicates significance difference
between NPs and free IR820.
As expected, NPs resulted in longer elimination half-lives, larger AUC, longer plasma
residence times, and slower body clearance rates than free IR820. The monoexponential
calculated plasma half-lives for free IR820, IR820-PGMD NPs, and DOX-IR820-PGMD
NPs were approximately 14.5 minutes, 19.5 minutes, and 18.7 minutes, respectively. The
bioavailability of IR820 is increased by using NPs, as the elimination half-life of IR820PGMD NPs and DOX-IR820-PGMD NPs is 1.4 times and 1.3 times the free IR820
elimination half-life, respectively. All the calculated physiology parameters indicated
prolonged blood circulation with nanoformulation and the cumulative exposure to body
organs is also enhanced, similar results were also reported in other studies (127, 128).
4.3.1.4.DOX pharmacokinetics modeling
Based on the loading efficiency of DOX in DOX-IR820-PGMD NPs, and an IR820 dose
of 0.24 mg/kg, the initial concentration of injected DOX in plasma was approximately 2
µg/mL. Therefore, the DOX plasma concentration of DOX-IR820-PGMD NPs at
different time points after injection was plotted in Figure 21.
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Figure 21. DOX plasma concentration at different time points after i.v. injection in DOXIR820-PGMD NP treatment.
We also used both one-compartment model and two-compartment model to assess the
goodness of model fit to the experimental data as shown in Table 12.
One-compartment model

Two-compartment model

Model equation

C(t)=1.985×e-0.66t

C t =1.356×e-1.167t +0.6535×e-0.0327t

R2

0.9453

0.9989

Table 12. Goodness of fit by using one or two-compartment model.
As shown in Table 12, it seems that the biexponential model may provide a better
understanding of our data as R2 was improved from 0.94 to 0.99 when a biexponential
model was used instead of a monoexponential model. Moreover, the introduction of
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distribution phase also gives us insight into the DOX-IR820-PGMD NPs distribution and
elimination behavior. Hence, we decided to calculate all the physiology parameters
following the use of a two-compartment model. All the values are shown in Table 13.
Distribution half-life (hours)

0.59±0.0008

Elimination half-life (hours)

21.2±0.028

AUC [µg*h/mL]

12.03±0.016

Mean plasma residence time, tp (h)

3.01±0.004

Total body clearance rate (mL/h)

0.5±0.0007

Table 13. Pharmacokinetic parameters from two-compartment analysis of dye data in
mice. Data represent mean ± S.D.
From Table 13, the calculated plasma half-lives were approximately 36 min (distribution
half-life) and 22 hours (elimination half-life). It seems DOX plasma half-life is also
enhanced when they are encapsulated in NPs. This is a significant improvement over
literature reports for free DOX which described a distribution half-life of ~2 minutes and
elimination half-life of ~10.3 hours in mice (129).
4.3.1.5. Organ dye content
Table 14 shows the average dye content in µg dye/g tissue for liver, lungs, intestines and
kidneys 24 hours after an i.v. injection of IR820, IR820-PGMD NPs, and DOX-IR820PGMD NPs. Our organ studies showed that IR820, both when in free form and
encapsulated into NPs, are processed primarily by hepatobiliary excretion and starts to
accumulate in the liver within 5-10 minutes after injection. However, organs such as the
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kidney and the lungs also have considerable contents of IR820 after 24 hours, indicating
uptake by the RES. DOX-IR820-PGMD NPs demonstrate significantly lower dye content
in the kidneys compared to the free dye (p=0.04), and 2.6 times smaller dye content in the
liver, although the latter did not reach a statistically significant difference from free
IR820 (p=0.08). As for the IR820-PGMD NPs, dye content was lower in kidneys and
lungs, but the difference also did not reach statistical significance. The lack of statistical
significance is probably due to the small number of subjects used in the study as well as
individual variability. DOX organ content after 24 hours injection was not detectable in
any tissue samples; that is, the DOX fluorescence intensity was not greater than the
background autofluorescence, probably due to the sub-therapeutic DOX dose used in this
study. Based on the results, we can say that DOX-IR820-PGMD NPs demonstrate
decreased renal clearance compared to free dye.
24h organ and plasma IR820 dye
content (n=3)

Liver
(µg/g)

Lungs
(µg/g)

Intestines
(µg/g)

Kidneys
(µg/g)

IR820

0.21±0.11

0.28±0.03

0.05±0.006 0.41±0.11

IR820-PGMD NPs

0.21±0.09

0.23±0.07

0.07±0.02

0.25±0.09

DOX-IR820-PGMD NPs

0.08±0.01

0.26±0.08

0.05±0.02

*0.21±0.04

Table 14. Quantitative organ content 24 hours after i.v. injection of IR820, IR820-PGMD
NPs, and DOX-IR820-PGMD NPs. Values represent average±SD. *P<0.05 indicates
significant difference between DOX-IR820-PGMD NPs and free IR820 values for
kidneys.
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CHAPTER 5: DISCUSSION AND CONCLUSIONS
5.1.Characterization of PGMD polymer
The MW of PGMD polymer is around 3000 Da, which is consistent with the literature
stating that polycondensation of monomers would preferentially yield low MW polymers
(130). When high MW polymers are desired, ring opening polymerization is preferred
(131). Jesus et al. synthesized a polyester dendritic scaffold based on the monomer unit
(2,2-bis(hydroxymethyl)propanoic acid), and measured a polymer MW around 4000 Da
(132). The PGMD NPs we obtained are in the 100-150 nm range, which can potentially
avoid premature clearance by the reticuloendothelial system (133). The loading of IR820
is sufficient to induce HT without causing cytotoxicity by NPs themselves. Loading of
IR820 and DOX into the PGMD NPs increased the PDI of the NPs as compared to void
NPs. Cheng et al. reported that increased PDI was observed with increasing loading
amount of docetaxel into PLGA–PEG (polyethylene glycol) NPs (134). The observed
increase in DOX-IR820-PGMD NPs zeta potential after addition of DOX and IR820 as
compared to void PGMD NPs may be caused by a zeta potential change towards neutral
due to incorporated DOX amino groups.
5.2.In vitro release of DOX and IR820
In our previous work, we developed a multifunctional system by loading ICG (as
imaging/HT agent) and DOX (chemotherapy agent) into PLGA NPs. Our studies showed
that ICG-DOX-PLGA NPs are able to bypass the P-gp pump in MES-SA/Dx5 cells and
are able to induce a synergistic effect by enhancing the cancer cell killing compared to
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chemotherapy alone or HT alone (106). However, DOX release from ICG-DOX-PLGA
loaded NPs is very slow with approximately 50% still retained in the NPs after 30-day
incubation in pH=7.4 phosphate buffered saline. The DOX release profile was not
improved even after exposing the NPs to NIR laser, which elevated the temperature to
~43°C due to the presence of the ICG. It seems that PLGA NPs are not sensitive to
external heat (~43°C) probably due to the high Tg (45°C-50°C) and high MW (40,00075,000 Da) of the PLGA used, which could have a large effect on the release rate (135).
Furthermore, the unmodified PLGA is hydrophobic, which in many cases limits its
applications to encapsulation of hydrophobic drugs.
The release of DOX from PGMD NPs was increased after exposure to laser. This is
perhaps because of the phase change of PGMD polymer (Tg=42.2°C) at high
temperatures, which increases the release of DOX from the polymer matrix. There are
several synthetic polymers sensitive to temperature change, such as acrylamide-based
hydrogels, especially poly[N-isopropylacrylamide] (PNIPA) hydrogel, and elastin-like
polypeptides (136-138). Zhang et al. reported that a synthetic PNIPA hydrogel releases
20-30% more of its 5-fluorouracil load at 37°C compared to 10°C (139). In addition,
acidic environment can also induce higher DOX and IR820 release, probably due to the
accelerated hydrolysis of PGMD polymer (140).
It is well documented that tumor interstitium has lower pH than blood and healthy tissue
(141, 142). Therefore, a rapid release of DOX from PGMD NPs in an acidic environment
could be beneficial in cancer therapy. Moreover, the heating of IR820 by an external NIR
laser can further induce release of DOX at tumor site. Generally, DOX release from the
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NPs was faster in the burst release phase as compared to our previous study of DOX
release from PLGA NPs (143), which is probably due to the fact that PGMD has a much
lower molecular weight compared to the PLGA used in that study (3 kDa v.s.75 kDa).
Zolnik reported that polymer MW is a key factor in determining release rate, and slow
release was observed in high MW polymers (70 kDa) (135). On the other hand, PGMD is
more hydrophilic than PLGA due to the addition of malic acid in the polycondensation
process. Thus, when using these two polymers to synthesize NPs, the PLGA NPs are
estimated to have a stronger hydrophobic-hydrophobic interaction with DOX than PGMD
NPs do, which could be another reason that a higher amount of DOX was released from
PGMD NPs compared to PLGA NPs for the same time period.
After exposure of the NPs to both acidic environment and laser irradiation, we observed a
further enhanced release of DOX from PGMD NPs. This is probably because of the
combination of physical and chemical effects as described above. The temperature of
NPs after laser exposure can increase the PGMD polymer Tg, which may cause the NPs’
physical properties to change resulting in the transition of amorphous materials from noncrystalline solid, relatively hard state to a molten state. The physicial property changes
could possibly soften the polymer and enlarge the NPs pore size, which may result in a
nonreversible increase in polymer hydrolysis since it becomes easier for water molecules
to penetrate the polymer and swell the particles. The enhanced hydrolysis could
accelerate the degradation of the polymer and induce higher diffusion of DOX from the
polymer matrix.
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5.3.Subcellular localization of DOX and IR820 in DOX-IR820-PGMD-NPs and
Uptake of NPs
In the subcellular localization study, DOX fluorescence was detected in both the cytosol
and the nucleus. We have demonstrated that the fate of PGMD NPs is mainly localizing
in lysosomes. Some of the NPs are able to escape endolysosomal degradation and release
their payload in the cytosol. The escape process primarily takes place through selective
reversal of the NPs’ surface charge (from anionic to cationic) in the acidic endolysosomal compartment, causing the NPs to interact with the endo-lysosomal
compartment membrane and to escape into the cytosol (144). The subcellular localization
of IR820 in both IR820-PGMD NPs and DOX-IR820-PGMD NPs treatments is very
similar since IR820, once released from NPs, possibly binds to cytoplasmic protein such
as ligandin (125).
The cellular uptake of NPs could be affected by their charge and shape. Zhang’s group
reported that spherical NPs had a higher cell entry rate into Chinese hamster ovary cells
than cylindrical NPs (145), whereas Chithrani et al. reported a lower uptake of rodshaped gold NPs into HeLa cells compared to spherical shaped NPs (146). On the other
hand, Liang et al. and Chung et al. reported that slight positively charged NPs gave the
greatest uptake efficiency as compared to neutral and negatively charged NPs (147, 148).
It seems spherical shape and slightly positive NPs are more efficiently taken up by cells
compared to other shapes and negatively charged NPs. These studies show that the
selection of the NPs are very important and can influence the NPs uptake by cells. Hence,
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the optimization of such parameters should be considered in the design of NPs in order to
improve the NPs delivery for various biomedical applications.
5.4.Cytotoxicity
The NPs result in significantly higher cell killing than does free IR820 or free IR820 plus
DOX in Dx5, but not in MES-SA cells. This is because MES-SA is a sensitive cell line
which does not overexpress P-gp, so the NPs do not provide an advantage in increasing
cellular uptake over the drug’s free form. All these results are in accord with the cellular
uptake study, in which we observed comparable DOX cellular uptake of DOX-IR820 and
DOX-IR820-PGMD NPs in MES-SA cells, whereas when the DOX was encapsulated in
the NPs, the result was a much higher uptake of DOX in Dx5 cells compared to the
uptake of DOX without the NPs. Our previous study of DOX-PLGA NPs had shown that
NPs can overcome the P-gp pump efflux effect and increase the uptake and cytotoxicity
in MDR cell lines, because the NPs formulation can protect the drug from being
recognized by the P-gp pump (35). Our current study result also showed that the drug
loaded NPs kill more Dx5 cells after exposure to laser as compared to free IR820 or free
IR820 plus DOX (p<0.05). Improved cancer cell killing can be achieved with a
combination of HT and chemotherapy. Our previous study demonstrated that mild cell
apoptosis can be induced by mild HT (106). Furthermore, the therapeutic effect of DOX
can be potentially augmented because mild HT can enhance cell membrane permeability
and fluidity, and in turn result in greater accumulation of the drug inside cancer cells,
especially for MDR cancer cells.
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In this study, we used two different heating modalities: 3 minutes laser/Dye/NP HT and 1
hour incubator HT, and the thermal doses for each were calculated to be approximately 3
minutes and 26 minutes, respectively, based on the CEM42 model. The model was
modified from the commonly used CEM43 model. IR820 was still able to cause a
temperature increase after laser exposure, even after being encapsulated into NPs, which
is comparable to the temperature increase achieved with free IR820. Thus, it was shown
in cytotoxicity studies that laser/Dye/NP induced HT caused significantly higher cell
killing than incubator HT, although a much lower thermal dose was given to the cells
(approximately 9 times less than with incubator HT). In the commonly used thermal dose
CEM43 model, in which thermal dose is normalized to cumulative equivalent minutes at
43°C (110), temperature and duration of heating can be used to define thermal damage.
Our previous paper and other groups’ reports demonstrated that the rate of photothermal
treatment might also be affecting HT outcome, since the cells are not able to initiate the
protective mechanism by inducing heat shock protein expression which would help to
reduce DNA damage (55, 149). Although the laser/Dye/NP HT produced approximately
9 times less thermal dose than incubator HT, it still resulted in significantly higher
cytotoxicity than incubator HT, thus confirming the importance of heating rate. Note that
the final temperature reached in both modes of HT was identical.
5.5. Study of ROS, HIF-1, and VEGF
Following the cytotoxicity study, we were interested in investigating the effect of rate and
amount of thermal dose to cells by exploring ROS generation, HIF-1 and VEGF
expression. HIF-1, as an important therapeutic target gene for cancer therapy, was studied
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after two different modes of HT. The purpose of this study was to find out what would be
a better strategy to apply HT and achieve the ideal therapeutic outcome.
It has been reported by Madamanchi’s group that ROS can up-regulate HSP70 protein
levels through the activation of binding of signal transducers and activators of
transcription (STATs) to the HSP70 promoters in vascular smooth muscle cells (VSMCs)
(105). This group exposed VSMCs to H2O2 and found that the cytoplasmic janus tyrosine
kinase 2 (JAK2)/STAT pathway can up-regulate HSP70 and minimize oxidative stress
effects on the cells.

The inhibition of HSP70 expression under laser/Dye/NP HT

probably means no enhancement of ROS production within the cells. Our ROS detection
experiments support this hypothesis, showing that no significant ROS was produced
inside the cells after laser/Dye/NP HT as compared to controls. However, when incubator
HT was used to mimic conditions more similar to whole body HT, we observed
significant intracellular ROS production. This result is consistent with Moon et al.
reporting that ROS was activated when a slow waterbath HT was applied to cells. HT can
activate the ERK pathway and increase NADPH oxidase activity, which leads to the
production of ROS (150). Based on our results, it seems that the application of rapid
laser/Dye/NP HT to cells will not induce an increase of ROS. However, the specific
mechanism of ROS abolishment within cells after laser/Dye/NP HT has to be further
studied.
Since there is no activation of ROS production in laser/Dye/NP HT treatment, we did not
observe enhanced HIF-1 expression either. However, HIF-1 up-regulation was observed
in slow and longer term HT, probably because ROS production was activated in the
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heating process. Other groups have also suggested that the presence of ROS is able to upregulate HIF-1 expression (99, 151). HIF-1 is very important as a therapeutic target
(152). Though traditional HT with slow and long-term heating appears beneficial as an
adjuvant therapy for radiotherapy and chemotherapy since it can hinder DNA damage
repair mechanisms and increase drug delivery (153, 154), this heating modality is also
able to induce up-regulation of HIF-1, and the overexpression of HIF-1 could
compromise the therapeutic effect by increasing drug resistance through up-regulation of
p-glycoprotein, and by reducing cancer cells drug senescence (155, 156). Our results
showed that VEGF secretion was also elevated along with the up-regulation of HIF-1,
which could potentially result in enhanced tumor angiogenesis.
The combination of HT and other therapies could elevate the HIF-1 expression to an even
higher extent than just a single therapy, which could alter tumor cell behavior and make
cells more aggressive. Therefore, it is important to review the possible molecular effects
of HT in considering its application as an adjuvant therapy, since other groups have
reported that HIF-1 can also be up-regulated by radiotherapy and chemotherapy (157159). Based on our study, IR820-PGMD NPs could be used for HT applications without
inducing the adverse effects of HIF-1. The HT therapeutic effect would be determined
more by the temperature and heating rate and perhaps less on the total thermal dose. By
using laser/Dye/NP HT, we did not observe enhancement of HIF-1 and VEGF
expression, but an improved therapeutic outcome was still achieved compared to
incubator HT. Despite these promising results for laser/Dye/NP HT, further studies
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should be performed to determine treatment parameters, such as how to efficiently
deliver these NPs and the timing for HT treatment relative to the chemotherapy.
5.6.In vivo studies
The nanoparticles we synthesized had a size around 100 nm diameter, which is
considered as an optimal size for particles and could possibility prolong the blood
circulation compared to larger or smaller particle sizes according to literatures reports
(127) (160). Therefore, it seems that our NPs should have an increased circulation time
profile as compared to their drug’s free form. In vivo imaging studies were done in
healthy mice. The mice imaging showed that NPs formulation enhanced IR820
fluorescence intensity as compared to free IR820 after 24 hours (P< 0.05 for in vivo
imaging studies). This is consistent with the literature reporting that nanoformulation or
liposomes can result in improved plasma circulation time and protect the loading agent
from degradation, which probably leads to the enhanced fluorescence intensity as
compared to free form (127, 161).
Our previous in vitro fluorescence intensity studies showed that the NPs resulted in about
8% fluorescence intensity decrease as compared to free IR820 at the same IR820
concentration, which may be due to the increased scattering within NPs. We have
observed similar phenomenon in our previous study of covalent IR820-PEG diamine
nanoconjugates (162). However, the stability of IR820 was enhanced as compared to free
IR820 as can be seen in Table 11. Our pharmacokinetics study showed that plasma has
significantly higher IR820 concentration in NPs form than free IR820 24h after injection.
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Based on available literature reports, nanoformulations also seem to result in improved
pharmacokinetic profiles, in many cases as a result of their size and surface properties,
ability to stabilize encapsulated drugs/dyes, and reduced liver metabolism and renal
clearance (127, 161). In addition, our biodistribution study showed that kidney IR820 dye
content was lower in NPs form than free IR820, and the difference between DOX-IR820PGMD NPs and free IR820 is significant, which means less IR820 was excreted through
the renal system when encapsulated in the NPs. When a one-compartment model was
used to study the physiology parameters of free IR820 and IR820 encapsulated NPs (both
DOX-IR820-PGMD NPs and IR820-PGMD NPs), the IR820 encapsulated NPs resulted
in much longer elimination half-lives, longer mean plasma residence time, larger overall
exposure as indicated by AUC, and slower clearance rate compared to free IR820. The
increased IR820 plasma half-life and prolonged circulation time in NPs formulation may
present an advantage over the free form by stabilizing the dye and allowing longer image
collection periods in imaging studies. Additionally, a widened therapeutic window may
be available when providing HT as an adjuvant therapy, thanks to prolonged exposure of
tissues to IR820. Since the EPR effect is proportional to the time and amount of drug/dye
circulating in blood (122), it would be reasonable for us to expect that NPs formulation
should result in higher accumulation and retention of IR820 in tumors. However, further
studies should be performed in a tumor-bearing model to support our hypothesis.
DOX plasma half-life is enhanced when it is encapsulated in NPs. Literature reports for
the plasma half-life of free DOX is ~2 minutes and elimination half-life of ~10.3 hours in
mice (129). Other researchers have also observed prolonged DOX plasma half-lives in
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different animal models when a nanoformulation, such as liposomes or NPs, was used
(119-121). For instance, Reddy et al. reported that DOX loaded poly(butyl cyanoacrylate)
NPs prolonged DOX half-life ~1.5 fold as compared to free DOX in rats (128). One of
the most important DOX-loaded liposome applications in clinical cancer therapy is DOXHCL encapsulated in pegylated liposomes for i.v. injection (DOXIL®). The
pharmacokinetics studies of DOXIL® in tumor-bearing mice followed a biexponential
curve, with the first distribution half-life of 1-3 hours, and a second elimination phase
half-life of 30-90 hours (121, 163, 164). Although DOX-IR820-PGMD NPs seem to have
shorter plasma half-life as compared to DOXil, they could also be pegylated and thus
longer plasma circulation time would be expected (165-167). The increased DOX plasma
half-life could have an impact on the therapeutic efficacy, because higher overall
exposure and prolonged exposure profiles can result in enhanced in vivo tumor uptake
and improved therapeutic efficacy.
5.7.Conclusions
In this study, multifunctional PGMD NPs were successfully synthesized to be used to
combine different therapeutic techniques such as chemotherapy and HT. The novelty of
this study is the synthesis of a thermal and pH sensitive polymer which provides a
controllable and predictable pharmacokinetic release profile using thermal or pH stimuli.
This novel and adjustable delivery vehicle was loaded with the chemotherapy agent DOX
and the imaging and HT agent IR820. The resulting NP formulations can be used to
improve cellular uptake and cytotoxicity in the MDR cancer cell line Dx5. The
combination of chemotherapy and HT also enhanced DOX cytotoxicity in both MES-SA
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and Dx5 compared to single therapy alone, indicating that less DOX can be used when
“adjuvant” cancer therapy is introduced. In vitro and in vivo studies showed that the NPs
yield higher IR820 fluorescence intensity than free IR820 after 24 hours, allowing longer
imaging collection times and potentially widening the window for HT applications.
Additionally, we proved in our study that using IR820-PGMD NPs, laser/Dye/NP HT
will not activate ROS expression and therefore would not induce HIF-1 and VEGF
expression. This lack of activation could yield a beneficial therapeutic outcome. In vivo
studies showed that the IR820 in NP formulation has a longer plasma half-life than free
IR820, providing longer imaging collection times for cancer diagnostics, and potentially
widening the window for HT applications. An increase in DOX plasma half-life was also
observed in NPs formulation, which could possibly result in an increased exposure of
tumor cells to the chemotherapeutic drug; coupled with the passive targeting provided by
the enhanced permeability and retention (EPR) effect may increase tumor uptake (168).
This could potentially lead to improvements in therapeutic efficacy. Thus, IR820-PGMD
NPs and DOX-IR820-PGMD NPs have promising applications as theranostic agents with
multifunctional imaging, HT and chemotherapy capabilities. This study is an extension to
the current knowledge of delivery of in vivo imaging probe, HT and chemotherapy in
NPs form, and we believe it will have significant impact to the application of
nanotechnology on cancer imaging and therapy.
5.8.Limitations and future work
Although the PGMD NPs seem to be promising in cancer diagnostic and therapy, more
studies have to be performed in order to confirm our hypothesis.
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1st. The FTIR spectrum only shows that presence of functional group C=O bond,
indicating polyester is forming in the PGMD polymer preparation, however it can not
give any information regarding to the composition of malic acid and DDA in PGMD
polymer. Polymer synthesis through thermal condensation method is a process called
step-growth polymerization by connecting two molecules and resulting in loss of small
molecules, which in our case is water. We have indirect evidence showing that malic acid
is included in the PGMD polymer and the change of DDA to malic acid ratio from 7:3 to
6:4 decreases the PGMD polymer Tg to between 40-41°C. However, Nuclear Magnetic
Resonance (NMR) spectroscopy should be acquired in order to address the questions of
PGMD polymer composition in the future work.
2nd . For the cellular response studies after heating by two different HT modalities, the
mechanism of inhibited ROS production after laser/Dye/NP HT is not clear and should be
further studied to prove that the ROS production inhibition is due to the small thermal
dose or due to the rapid thermal heating rate, or the effect of both. In terms of molecular
biology, different inhibitors should be used to block corresponding ROS production
pathways and to find out exactly which pathway is used by cells to suppress the ROS
production.
In addition, the measurement of HIF-1 and VEGF expression after different HT were
done in cells, which might provide valuable but limited information due to the large
difference between an in vitro and in vivo model. Therefore, in vivo model with tumorbearing mice should be used to further study the in vivo HIF-1 and VEGF expression.
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3rd . Although PGMD NPs resulted in a significant enhancement of blood circulation of
DOX and IR820 in healthy mice, more studies must be done to further improve the NPs
delivery. Loss of NPs during the transporting to tumors in plasma circulation often
happens due to the binding of NPs to serum proteins known as surface opsonization,
which results in the NPs being recognized and cleared by phagocytes or marcophages
(161, 169). Modification of NPs surface with polyethylene glycol (PEG) can improve
plasma circulation time and enhanced tumor uptake as compared to their non-PEGylated
counterparts (165-167), which is possibly related to the surface charge of NPs and the
protection of PEG to reduce albumin protein binding (127, 169). These reports indicated
that modifying the NPs surface with PEG could be promising in enhancement of NPs
delivery. Thus, one consideration to improve the NPs delivery is to formulate PEGylated
PGMD NPs.
4th . Another consideration is to formulate the NPs for targeting to achieve optimal
delivery. As discussed before in the introduction section, antibody/ligand targeted NPs
have better accumulation efficiency than their non-counjugated counterparts. The
therapeutic potential of nanocarriers can be further magnified by tagging them with
appropriate ligands that selectively interact with tumor cell membrane receptors. This
method of tagging the drug delivery vehicle with a ligand and allowing it to specifically
sequester in the targeted tumor is an example of active targeting and could confer greater
specificity to different types of tumors. Therefore, PGMD NPs can be surface modified to
conjugate different ligands or antibodies to further improve the specificity to tumor sites
and uptake into cancer cells.
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